Method of using 5-arylheteroarylalkyl-1,3 5-trisubstituted-1,24-triazole compounds for treatment of circulatory disorders

ABSTRACT

A class of 5-arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds is described for use in treatment of circulatory disorders such as hypertension. Compounds of particular interest are angiotensin II antagonists of the formula ##STR1## wherein A is selected from ##STR2## wherein m is one; wherein R 1  is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, benzyl, cyclohexyl, cyclohexylmethyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R 2  is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl, neo-pentyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxypentyl, halo, difluoromethyl, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl, 1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl, cyclohexylmethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein each of R 3 , R 4 , R 6  through R 11  is hydrido and R 5  is selected from COOH, SH, PO 3  H 2 , SO 3  H, CONHNH 2 , CONHNHSO 2  CF 3 , OH, ##STR3## wherein each of R 42  and R 43  is independently selected from chromo, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl.

This is a division of application Ser. No. 07/903,594 filed Jun. 24,1991, now abandoned which is a division of application Ser. No.07/674,276 filed Mar. 21, 1991 now U.S. Pat. No. 5,196,537.

FIELD OF THE INVENTION

Non-peptidic 5-arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazolecompounds are described for use in treatment of circulatory disorderssuch as hypertension arid congestive heart failure. Of particularinterest are angiotensin II antagonist compounds provided by1,2,4-triazoles having a heteroarylmethyl moiety attached to the carbonatom at the five-position of the 1,2,4-triazole.

BACKGROUND OF THE INVENTION

The renin-angiotensin system is one of the hormonal mechanisms involvedin regulation of pressure/volume homeostasis and in expression ofhypertension. Activation of the renin-angiotensin cascade begins withrenin secretion from the juxtaglomerular apparatus of the kidney andculminates in the formation of angiotensin II, the primary activespecies of this system. This octapeptide, angiotensin II, is a potentvasoconstrictor agent and also produces other physiological effects suchas promoting aldosterone secretion, promoting sodium and fluidretention, inhibiting renin secretion, increasing sympathetic nervoussystem activity, increasing vasopressin secretion, causing positivecardiac inotropic effect and modulating other hormonal systems.

Previous studies have shown that antagonizing angiotensin II at itsreceptors is a viable approach to inhibit the renin-angiotensin system,given the pivotal role of this octapeptide which mediates the actions ofthe renin-angiotensin system through interaction with various tissuereceptors. There are several known angiotensin II antagonists, most ofwhich are peptidic in nature. Such peptidic compounds are of limited usedue to their lack of oral bioavailability or their short duration ofaction. Also, commercially-available peptidic angiotensin II antagonists(e.g., Saralasin) have a significant residual agonist activity whichfurther limit their therapeutic application.

Non-peptidic compounds with angiotensin II antagonist properties areknown. For example, the sodium salt of2-n-butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5-acetic acid hasspecific competitive angiotensin II antagonist activity as shown in aseries of binding experiments, functional assays and in vivo tests [P.C. Wong et al, J. Pharmacol. Exp. Ther., 247 (1), 1-7 (1988)]. Also, thesodium salt of 2-butyl-4-chloro-1-(2-nitrobenzyl)imidazole-5-acetic acidhas specific competitive angiotensin II antagonist activity as shown ina series of binding experiments, functional assays and in vivo tests [A.T. Chiu et al, European J. Pharmacol., 157, 3121 (1988)]. A family of1-benzylimidazole-5-acetate derivatives has been shown to havecompetitive angiotensin II antagonist properties [A. T. Chiu et al, J.Pharmacol. Exp. Ther., 250(3), 867-874 (1989)]. U.S. Pat. No. 4,816,463to Blankey et al describes a family of4,5,6,7-tetrahydro-1H-imidazo(4,5-c)-tetrahydro-pyridine derivativesuseful as antihypertensives, some of which are reported to antagonizethe binding of labelled angiotensin II to rat adrenal receptorpreparation and thus cause a significant decrease in mean arterial bloodpressure in conscious hypertensive rats. EP No. 253,310, published 20Jan. 1988, describes a series of aralkyl imidazole compounds, includingin particular a family of biphenylmethyl substituted imidazoles, asantagonists to the angiotensin II receptor. EP No. 323,841 published 12Jul. 1989 describes four classes of angiotensin II antagonists, namely,biphenylmethylpyrroles, biphenylmethylpyrazoles,biphenylmethyl-1,2,3-triazoles and biphenylmethyl4-substituted-4H-1,2,4-triazoles, including the compound3,5-dibutyl-4-[(2'-carboxybiphenyl-4-yl)methyl]-4H-1,2,4-triazole. U.S.Pat. No. 4,880,804 to Carini et al describes a family ofbiphenylmethylbenzimidazole compounds as angiotensin II receptorblockers for use in treatment of hypertension and congestive heartfailure.

There are several families of known compounds having one or two oxosubstituents on the triazole ring. For example, East German Patent No.160,447 published 3 Aug. 1983 describes a family of1,2,4-triazolin-5-one compounds, specifically2,4-dihydro-4,5-bis(phenylmethyl)-3H-1,2,4-triazol-3-one, for use asherbicides. Belgian Patent No. 806,146 published 16 Oct. 1972 describesa family of triazolinone compounds, including the compound(3-(4-m-chlorophenyl-1-piperazinyl)-propyl)-3,4-diethyl-1,2,4-triazolin-5-one,having tranquilizer, hypotensive and analgesic activities. BelgianPatent No. 631,842 published 28 Feb. 1963 describes a family of1,2,4-triazolones having hypnotic, tranquilizer, narcotic, sedative andanalgetic activities, which includes a class of4-N-aralkyl-1,2,4-triazol-5-one compounds. EP #7,180 published 15 Jun.1978 describes a family of1,2-disubstituted-4-alkyl-1,2,4-triazolidine-3,5-dione compounds havinga wide variety of activities, such as antiulcer, bronchodilator,antifertility and cardiovascular-related activities which includeantihypertensive, antiarrhythmic, platelet aggregation inhibition andsmooth muscle activities. EP # 283,310 published 18 Mar. 1987 describesa family of N¹ -diarylmethyl-N² -aminoalkyl-diaza-heterocyclicderivatives for treating cerebral vascular and ischmic diseases and forprotecting against anoxia.

DESCRIPTION OF THE INVENTION

A class of 5-arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazolecompounds useful in treating circulatory disorders, particularlycardiovascular disorders, is defined by Formula I: ##STR4## wherein A isselected from ##STR5## wherein m is a number selected from one to four,inclusive; wherein R¹ is selected from hydrido, alkyl, hydroxyalkyl,haloalkyl, cycloalkyl, cycloalkylalkyl, formyl, aralkyl, aryl, aroyl,alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkenyl,cycloalkenyl, aralkoxycarbonyl, alkynyl, alkylthiocarbonyl,alkylthiothiocarbonyl, arylthiocarbonyl, arylthiothiocarbonyl,aralkylthiocarbonyl, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl,aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroarylhaving one or more ring atoms selected from oxygen, sulfur and nitrogenatoms, and amido radicals of the formula ##STR6## wherein X is oxygenatom or sulfur atom; wherein each of R¹² and R¹³ is independentlyselected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino,dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl andaryl, and wherein R¹² and R¹³ taken together may form a heterocyclicgroup having five to seven ring members including the nitrogen atom ofsaid amido radical and which heterocyclic group may further contain oneor more hetero atoms as ring members selected from oxygen, nitrogen andsulfur atoms and which heterocyclic group may be saturated or partiallyunsaturated; wherein each of R¹² and R¹³ taken together may form anaromatic heterocyclic group having five ring members including thenitrogen atom of said amido radical and which aromatic heterocyclicgroup may further contain one or more additional nitrogen atoms;

wherein each of R² through R¹¹ is independently selected from hydrido,alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,cycloalkylhaloalkyl, cycloalkylcarbonyl, formyl, alkoxy, aralkyl,aralkylhaloalkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy,alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkenyl,cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl,alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl,mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio,cycloalkylthio, cycloalkylalkylthio, alkylthiocarbonyl,alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio,alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio,arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy,arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio,aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio,aralkylthiocarbonyloxy, aralkylthiocarbonylthio, alkylthiocarbonyl,aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl,aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl,phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl,cycloheteroalkyl, cycloheteroalkylalkyl andcycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- andcyclohetero-containing groups has one or more ring atoms selected fromoxygen, sulfur and nitrogen atoms, and wherein each of R² through R¹¹may be further independently selected from amino and amido radicals ofthe formula ##STR7## wherein X is oxygen atom or sulfur atom; whereineach n is a number independently selected from zero to six, inclusive;

wherein each of R¹⁴ through R²⁶ is independently selected from hydrido,alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino,hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, andwherein R¹⁴ and R¹⁵ taken together, R¹⁶ and R¹⁷ taken together, R¹⁸ andR¹⁹ taken together, R²¹ and R²² taken together and R²³ and R²⁴ takentogether may each form a heterocyclic group having five to seven ringmembers including the nitrogen atom of said amino or amido radical andwhich heterocyclic group may further contain one or more hetero atoms asring members selected from oxygen, nitrogen and sulfur atoms and whichheterocyclic group may be saturated or partially unsaturated; whereinR¹⁴ and R¹⁵ taken together, R¹⁶ and R¹⁷ taken together, R²¹ and R²²taken together and R²³ and R²⁴ taken together may each form an aromaticheterocyclic group having five ring members including the nitrogen atomof said amino or amido radical and which aromatic heterocyclic group mayfurther contain one or more hetero atoms as ring atoms selected fromoxygen, nitrogen and sulfur atoms;

and wherein each of R³ through R¹¹ may be further independently selectedfrom hydroxy and acidic moieties of the formula

    --Y.sub.n A

wherein n is a number selected from zero through three, inclusive, andwherein A is an acidic group selected to contain at least one acidichydrogen atom, and the amide, ester and salt derivatives of said acidicmoieties; wherein Y is a spacer group independently selected from one ormore of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl,aralkyl and heteroaryl having one or more ring atoms selected fromoxygen, sulfur and nitrogen atoms;

and wherein any of the foregoing R¹ through R²⁶, Y and A groups having asubstitutable position may be substituted by one or more groupsindependently selected from hydroxy, alkyl, alkenyl, alkynyl, aralkyl,hydroxyalkyl, haloalkyl, halo, oxo, alkoxy, aryloxy, aralkoxy,aralkylthio, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aroyl,cycloalkenyl, cyano, cyanoamino, nitro, alkylcarbonyloxy,alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl,carboxyl, mercapto, mercaptocarbonyl, alkylthio, arylthio,alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl,aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroarylhaving one or more ring atoms selected from oxygen, sulfur and nitrogenatoms, and amino and amido radicals of the formula ##STR8## wherein X isoxygen atom or sulfur atom; wherein each of R²⁷ through R³¹ isindependently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl,aralkyl, aryl, DR³² and ##STR9## wherein D is selected from oxygen atomand sulfur atom and R³² is selected from hydrido, alkyl, cycloalkyl,cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁷, R²⁸, R²⁹, R³⁰,R³¹, R³³ and R³⁴ is independently selected from hydrido, alkyl,cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl,alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl,alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl,haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁷, R²⁸, R²⁹,R³⁰, R³¹, R³³ and R³⁴ is further independently selected from amino andamido radicals of the formula ##STR10## wherein X is oxygen atom orsulfur atom; wherein each of R³⁵, R³⁶, R³⁷ R³⁸, R³⁹ and R⁴⁰ isindependently selected from hydrido, alkyl, cycloalkyl, cyano,hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl,haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁸ and R²⁹taken together and each of R³⁰ and R³¹ taken together may form aheterocyclic group having five to seven ring members including thenitrogen atom of said amino or amido radical, which heterocyclic groupmay further contain one or more hetero atoms as ring members selectedfrom oxygen, nitrogen and sulfur atoms and which heterocyclic group maybe saturated or partially unsaturated; wherein each of R²⁸ and R²⁹ takentogether and each of R³³ and R³⁴ taken together may form an aromaticheterocyclic group having five ring members including the nitrogen atomof said amino or amido radical and which aromatic heterocyclic group mayfurther contain one or more hetero atoms as ring atoms selected fromoxygen, nitrogen and sulfur atoms; or a tautomer thereof or apharmaceutically-acceptable salt thereof.

Compounds of Formula I would be useful in treating a variety ofcirculatory disorders, including cardiovascular disorders, such ashypertension, congestive heart failure and arteriosclerosis, and totreat other disorders such as glaucoma. These compounds would also beuseful as adjunctive therapies. For example, compounds of Formula I maybe used in combination with other drugs, such as a diuretic, to treathypertension. Also, compounds of Formula I could be used in conjunctionwith certain surgical procedures. For example, these compounds could beused to prevent post-angioplasty re-stenosis. Compounds of Formula I aretherapeutically effective in treatment of cardiovascular disorders byacting as antagonists to, or blockers of, the angiotensin II (AII)receptor. Compounds of Formula I would be therapeutically effective intreatment of the above-mentioned circulatory and cardiovasculardisorders or would be precursors to, or prodrugs of,therapeutically-effective compounds.

The phrase "acidic group selected to contain at least one acidichydrogen atom", as used to define the --Y_(n) A moiety, is intended toembrace chemical groups which, when attached to any of the R³ throughR¹¹ positions of Formula I, confers acidic character to the compound ofFormula I. "Acidic character" means proton-donor capability, that is,the capacity of the compound of Formula I to be a proton donor in thepresence of a proton-receiving substance such as water. Typically, theacidic group should be selected to have proton-donor capability suchthat the product compound of Formula I has a pK_(a) in a range fromabout one to about twelve. More typically, the Formula I compound wouldhave a pK_(a) in a range from about two to about seven. An example of anacidic group containing at least one acidic hydrogen atom is carboxylgroup (--COOH). Where n is zero and A is --COOH, in the --Y_(n) Amoiety, such carboxyl group would be attached directly to one of the R³through R¹¹ positions. The Formula I compound may have one --Y_(n) Amoiety attached at one of the R³ through R¹¹ positions, or may have aplurality of such --Y_(n) A moieties attached at more than one of the R³through R¹¹ positions, up to a maximum of nine such -- Y_(n) A moieties.There are many examples of acidic groups other than carboxyl group,selectable to contain at least one acidic hydrogen atom. Such otheracidic groups may be collectively referred to as "bioisosteres ofcarboxylic acid" or referred to as "acidic bioisosteres". Specificexamples of such acidic bioisosteres are described hereinafter.Compounds of Formula I having the --Y_(n) A moiety attached at one ofpositions R⁵, R⁶, R⁸ and R⁹ would be expected to have preferredproperties, while attachment at R⁵ or R⁹ would be more preferred.Compounds of Formula I may have one or more acidic protons and,therefore, may have one or more pK_(a) values. It is preferred, however,that at least one of these pK_(a) values of the Formula I compound asconferred by the --Y_(n) A moiety be in a range from about two to aboutseven. The --Y_(n) A moiety may be attached to one of the R³ through R¹¹positions through any portion of the --Y_(n) A moiety which results in aFormula I compound being relatively stable and also having a labile oracidic proton to meet the foregoing pK_(a) criteria. For example, wherethe --Y_(n) A acid moiety is tetrazole, the tetrazole is attached at thering carbon atom.

A preferred class of compounds consists of those compounds of Formula Iwherein m is one; wherein R¹ is selected from hydrido, alkyl,hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl,aroyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl,cycloalkenyl, alkynyl, cycloalkynyl, carboxyl, alkylthiocarbonyl,arylthiocarbonyl, arylthiothiocarbonyl, aralkylthiocarbonyl,alkylsulfonyl, aralkylsulfonyl, arylsulfonyl, heteroaryl having one ormore ring atoms selected from oxygen, sulfur and nitrogen atoms, andamido radicals of the formula ##STR11## wherein X is oxygen atom orsulfur atom; wherein each of R¹² and R¹³ is independently selected fromhydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino,hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;

wherein R² is selected from hydrido, alkyl, hydroxyalkyl, halo,haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, aroyl,aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl,alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano,nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl,alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,mercaptocarbonyl, mercaptothiocarbonyl, mercaptoalkyl,alkoxycarbonyloxy, alkylthio, cycloalkylthio, cycloalkylalkylthio,alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy,alkylthiocarbonylthio, alkylthiothiocarbonyl, alkylthiothiocarbonylthio,arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy,arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio,aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio,aralkylthiocarbonyloxy, aralkylthiocarbonylthio, aralkylthiocarbonyl,aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl,aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl,phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl,cycloheteroalkyl, cycloheteroalkylalkyl andcycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- andcycloheteroalkyl-containing groups has one or more hetero ring atomsselected from oxygen, sulfur and nitrogen atoms, and wherein each of R²through R¹¹ may be further independently selected from amino and amidoradicals of the formula ##STR12## wherein X is selected from oxygen atomor sulfur atom; wherein each n is a number independently selected fromzero to six, inclusive;

wherein each of R¹⁴ through R²⁶ is independently selected from hydrido,alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino,hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;

wherein each of R³ through R¹¹ is independently selected from hydrido,hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl,cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy,alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl,alkynyl, cycloalkynyl, cyano, nitro, carboxyl, alkylcarbonyloxy,mercaptocarbonyl, mercaptothiocarbonyl, alkoxycarbonyloxy, alkylthio,alkylthiocarbonyl, alkylcarbonylthio, alkylthiocarbonyloxy,alkylthiocarbonylthio, alkylthiothiocarbonyl, arylthio,arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy,arylthiothiocarbonyl, aralkylthio, aralkylthiocarbonyl,aralkylcarbonylthio, aralkylthiocarbonyloxy, aralkylthiocarbonylthio,aralkylthiocarbonyl, aralkylthiocarbonylthio, mercapto, alkylsulfonyl,aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of theformula ##STR13## wherein X is oxygen atom or sulfur atom; wherein eachof R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ is independently selected fromhydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, cycloalkylalkyl,alkoxyalkyl, aralkyl and aryl;

and wherein each of R³ through R¹¹ may be further independently selectedfrom acidic moieties of the formula

    --Y.sub.n A

wherein n is a number selected from zero through three, inclusive;wherein A is an acidic group selected from acids containing one or moreatoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, andwherein said acidic group is selected to contain at least one acidichydrogen atom, and the amide, ester and salt derivatives of said acidicmoieties; wherein Y is a spacer group independently selected from one ormore of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl,aralkyl and heteroaryl having one or more ring atoms selected fromoxygen, sulfur and nitrogen atoms;

and wherein any of the foregoing R¹ through R²⁶, Y and A groups having asubstitutable position may be substituted by one or more groupsindependently selected from hydroxy, alkyl, alkenyl, aralkyl,hydroxyalkyl, halo, haloalkyl, oxo, alkoxy, aryloxy, aralkoxy,alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro,alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, mercaptocarbonyl,alkylthio and alkylthiocarbonyl, and amino and amido radicals of theformula ##STR14## wherein X is oxygen atom or sulfur atom; wherein eachof R²⁷ through R³¹ is independently selected from hydrido, alkyl,cycloalkyl, cycloalkylalkyl, aralkyl, aryl, and DR³² and ##STR15##wherein D is selected from oxygen atom and sulfur atom, and R³² isselected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl andaryl; wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³³ and R³⁴ isindependently selected from hydrido, alkyl, cycloalkyl, cyano,hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl,alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyland aryl;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

A more preferred class of compounds consists of those compounds ofFormula I wherein m is one; wherein R¹ is selected from alkyl,hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl,aroyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl,cycloalkenyl, alkynyl, cycloalkynyl, carboxyl, alkylsulfonyl,aralkylsulfonyl and arylsulfonyl, and amido radicals of the formula##STR16## wherein each of R¹² and R¹³ is independently selected fromhydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino,hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;

wherein R² is selected from hydrido, alkyl, hydroxyalkyl, halo,haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, aroyl,aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl,alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano,nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptocarbonyl,alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, alkylthio,cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio,aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl,aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl,phthalimido, phthalimidoalkyl, heteroaryl, heteroarylalkyl,cycloheteroalkyl, cycloheteroalkylalkyl andcycloheteroalklylcarbonylalkyl wherein each of said heteroaryl- andcycloheteroalkyl-containing groups has one or more hetero ring atomsselected from oxygen, sulfur and nitrogen atoms, and wherein R² may befurther selected from amino and amido radicals of the formula ##STR17##wherein X is selected from oxygen atom or sulfur atom; wherein each n isa number independently selected from zero to six, inclusive;

wherein each of R¹⁴ through R²⁶ is independently selected from hydrido,alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino,hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;

wherein each of R³ through R¹¹ is independently selected from hydrido,hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, alkoxy,aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl,alkylcarbonyloxy, mercaptocarbonyl, alkoxycarbonyloxy, alkylthio,arylthio, aralkylthio, mercapto, alkylsulfonyl, aralkylsulfonyl andarylsulfonyl, and amino and amido radicals of the formula ##STR18##wherein each of R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ is independentlyselected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino,dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl andaryl;

and wherein each of R³ through R¹¹ may be further independently selectedfrom acidic moieties of the formula

    --Y.sub.n A

wherein n is a number selected from zero through three, inclusive;

wherein the A group is selected to have an acidic proton, such that whenthe --Y_(n) A moiety is incorporated within a compound of Formula I,there is provided a compound of Formula I having a pK_(a) in a rangefrom about two to about seven, said A group selected from carboxylicacid and bioisosteres of carboxylic acid selected from ##STR19## whereineach W is independently selected from oxygen atom, sulfur atom and NR³⁹; wherein each of R³⁵, R³⁶, R³⁷, R³⁸ and R³⁹ is independently selectedfrom hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl,cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R³⁵, R³⁶,R³⁷ and R³⁹ may be further independently selected from amino radical ofthe formula ##STR20## wherein each of R⁴⁰ and R⁴¹ is independentlyselected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl,cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein R⁴⁰ and R⁴¹taken together may form a heterocyclic group having five to seven ringmembers including the nitrogen atom of said amino radical, whichheterocyclic group may further contain one or more hetero atoms as ringmembers selected from oxygen, nitrogen and sulfur atoms and whichheterocyclic group may be saturated or partially unsaturated; whereinR⁴⁰ and R⁴¹ taken together may form an aromatic heterocyclic grouphaving five ring members including the nitrogen atom of said aminoradical and which aromatic heterocyclic group may further contain one ormore hetero atoms as ring atoms selected from oxygen, nitrogen andsulfur atoms; wherein each of R³⁶ and R³⁷ may be further independentlyselected from hydroxy, alkoxy, alkylthio, aryloxy, arylthio, aralkylthioand aralkoxy; and the amide, ester and salt derivatives of said acidicgroups;

wherein said bioisostere of carboxylic acid may be further selected fromheterocyclic acidic groups consisting of heterocyclic rings of four toabout nine ring members, which heterocyclic ring contains at least onehetero atom selected from oxygen, sulfur and nitrogen atoms, whichheterocyclic ring may be saturated, fully unsaturated or partiallyunsaturated, and which heterocyclic ring may be attached at a singleposition selected from R³ through R¹¹ or may be attached at any twoadjacent positions selected from R³ through R¹¹ so as to form afused-ring system with one of the phenyl rings of Formula I; and theamide, ester and salt derivatives of said heterocyclic acidic groups;

wherein Y is a spacer group independently selected from one or more ofalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl;

and wherein any of the foregoing R¹ through R²⁶ and R³⁵ through R⁴¹, Yand A groups having a substitutable position may be substituted by oneor more groups independently selected from hydroxy, alkyl, alkenyl,aralkyl, hydroxyalkyl, halo, oxo, haloalkyl, alkoxy, aryloxy, aralkoxy,alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro,alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, mercaptocarbonyl,alkylthio and alkylthiocarbonyl, and amino and amido radicals of theformula ##STR21## wherein X is selected from oxygen atom and sulfuratom; wherein R²⁷ is selected from hydrido, alkyl, cycloalkyl,cycloalkylalkyl, aralkyl, aryl and DR³² and ##STR22## wherein D isselected from oxygen atom and sulfur atom; wherein R³² is selected fromhydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl;

wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³³ and R³⁴ is independentlyselected from hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl,haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl,carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

An even more preferred class of compounds consists of those compounds ofFormula I wherein m is one; wherein R¹ is selected from hydrido, alkyl,hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl,aroyl, alkoxyalkyl, alkylcarbonyl, alkenyl, cycloalkenyl, alkynyl,mercaptocarbonyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl and amidoradicals of the formula ##STR23## wherein each of R¹² and R¹³ isindependently selected from hydrido, alkyl, cycloalkyl, cyano, amino,monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl,alkoxyalkyl, aralkyl and aryl;

wherein R² is selected from hydrido, alkyl, hydroxyalkyl, halo,haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, aroyl,aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl,alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano,nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl,alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio,cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio, mercapto,alkylsulfinyl, alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl,arylsulfinyl, arylsulfonyl, phthalimido, phthalimidoalkyl, heteroaryl,heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl andcycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- andcycloheteroalkyl-containing groups has one or more hetero ring atomsselected from oxygen, sulfur and nitrogen atoms, and wherein each of R²through R¹¹ may be further independently selected from amino and amidoradicals of the formula ##STR24## wherein X is selected from oxygen atomand sulfur atom; wherein each n is a number independently selected fromzero to six, inclusive;

wherein each of R¹⁴ through R²⁶ is independently selected from hydrido,alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino,hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;

wherein each of R³ through R¹¹ is independently selected from hydrido,hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, alkoxy,aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl,alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl,alkylthio, aralkylthio and mercapto;

and wherein each of R³ through R¹¹ may be further independently selectedfrom acidic moieties of the formula

    --Y.sub.n A

wherein n is a number selected from zero through three, inclusive;wherein A is selected from carboxylic acid and bioisosteres ofcarboxylic acid selected from ##STR25## wherein each W is independentlyselected from oxygen atom, sulfur atom and NR³⁹ ; wherein each of R³⁵,R³⁸ and R³⁹ is independently selected from hydrido, alkyl, haloalkyl,haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, cycloalkylalkyl, aryland aralkyl; wherein each of R³⁵ and R³⁹ may be further independentlyselected from amino radical of the formula ##STR26## wherein each of R⁴⁰and R⁴¹ is independently selected from hydrido, alkyl, cycloalkyl,hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl,and wherein R⁴⁰ and R⁴¹ taken together may form a heterocyclic grouphaving five to seven ring members including the nitrogen atom of saidamino radical, which heterocyclic group may further contain one or morehetero atoms as ring members selected from oxygen, nitrogen and sulfuratoms, and which heterocyclic group may be saturated or partiallyunsaturated; wherein R⁴⁰ and R⁴¹ taken together may form an aromaticheterocyclic group having five ring members including the nitrogen atomof said amino radical and which aromatic heterocyclic group may furthercontain one or more hetero atoms as ring atoms selected from oxygen,nitrogen and sulfur atoms; and the amide, ester and salt derivatives ofsaid acidic groups; wherein said bioisostere of carboxylic acid may befurther selected from heterocyclic acidic groups consisting ofheterocyclic rings of four to about nine ring members, which ringcontains at least one hetero atom, selected from oxygen, sulfur andnitrogen atoms, which heterocyclic ring may be saturated, fullyunsaturated or partially unsaturated, and which heterocyclic ring may beattached at a single position selected from R³ through R¹¹ or may beattached at any two adjacent positions selected from R³ through R¹¹ soas to form a fused-ring system with one of the phenyl rings of FormulaI; and the amide, ester and salt derivatives of said heterocyclic acidicgroups;

wherein Y is a spacer group independently selected from one or more ofalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl;

wherein each of R¹ through R²⁶, R³⁵ and R³⁸ through R⁴¹, Y and Aindependently may be substituted at any substitutable position with oneor more groups selected from alkyl, hydroxy, halo, oxo, haloalkyl,alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl,aralkyl, alkoxy, aryloxy and aralkoxy;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

A highly preferred class of compounds within Formula I consists of thosecompounds wherein m is one; wherein R¹ is selected from hydrido, alkyl,hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl,aroyl, alkoxyalkyl, alkylcarbonyl, alkenyl, alkynyl, alkylsulfonyl,aralkylsulfonyl, arylsulfonyl and amido radicals of the formula##STR27## wherein each of R¹² and R¹³ is independently selected fromhydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl,phenalkyl and phenyl;

wherein R² is selected from hydrido, alkyl, hydroxyalkyl, halo,haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, benzoyl,phenoxy, phenoxyalkyl, phenalkyloxy, phenylthio, phenalkylthio,aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl,cycloalkenyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl,alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl,mercaptoalkyl, alkoxycarbonyloxy, alkylthio, cycloalkylthio,cycloalkylalkylthio, phthalimido, phthalimidoalkyl, heteroaryl,heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl andcycloheteroalkylcarbonylalkyl wherein each of said heteroaryl- andcycloheteroalkyl-containing groups has one or more hetero ring atomsselected from oxygen, sulfur and nitrogen atoms, and wherein each of R²through R¹¹ may be further independently selected from amino and amidoradicals of the formula ##STR28## wherein X is selected from oxygen atomand sulfur atom; wherein each n is a number independently selected fromzero to six, inclusive;

wherein each of R¹⁴ through R²⁶ is independently selected from hydrido,alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyland phenyl;

wherein each of R³ through R¹¹ is independently selected from hydrido,hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, alkoxy,phenalkyl, phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl,alkylcarbonyl, alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl,alkylthio and mercapto;

and wherein each of R³ through R¹¹ may be further independently selectedfrom acidic moieties of the formula

    --Y.sub.n A

wherein n is a number selected from zero through two, inclusive; whereinA is selected from carboxylic acid and bioisosteres of carboxylic acidselected from ##STR29## wherein each W is independently selected fromoxygen atom, sulfur atom and NR³⁹ ; wherein each of R³⁵, R³⁸ and R³⁹ isindependently selected from hydrido, alkyl, haloalkyl,haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl;wherein each of R³⁵ and R³⁹ may be further independently selected fromamino radical of the formula ##STR30## wherein each of R⁴⁰ and R⁴¹ isindependently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl,haloalkyl, alkoxyalkyl, benzyl and phenyl; and the amide, ester and saltderivatives of said acidic groups;

wherein said bioisostere of carboxylic acid may be further selected fromheterocyclic acidic groups consisting of heterocyclic rings of four toabout nine ring members, which ring contains at least one hetero atom,selected from oxygen, sulfur and nitrogen atoms, which heterocyclic ringmay be saturated, fully unsaturated or partially unsaturated, and whichheterocyclic ring may be attached at a single position selected from R³through R¹¹ or may be attached at any two adjacent positions selectedfrom R³ through R¹¹ so as to form a fused-ring system with one of thephenyl rings of Formula I; and the amide, ester and salt derivatives ofsaid heterocyclic acidic groups;

wherein Y is a spacer group independently selected from one or more ofalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, phenyl, phenalkyl andaralkyl;

wherein each of R¹ through R²⁶, R³⁵ and R³⁸ through R⁴¹, Y and A andindependently may be substituted at any substitutable position with oneor more groups selected from alkyl, cycloalkyl, cycloalkylalkyl,hydroxy, halo, oxo, haloalkyl, alkoxycarbonyl, cyano, nitro,alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy andaralkoxy;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

An even more highly preferred class of compounds consists of thosecompounds of Formula I wherein m is one; wherein R¹ is selected fromhydrido, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl,aralkyl, aryl, benzoyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl,alkenyl and alkynyl;

where R² is selected from alkyl, aminoalkyl, hydroxyalkyl, halo,haloalkyl, cycloalkyl, cycloalkylalkyl, alkylcarbonyl,cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy, aralkyl,aralkylhaloalkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy,phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, acetyl,alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl,carboxyalkyl, alkylcarbonyloxy, mercaptoalkyl, mercaptocarbonyl,alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, phthalimido,phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl, alkylthio,cycloalkylthio, cycloalkylalkylthio, and amino and amido radicals of theformula ##STR31## wherein X is selected from oxygen atom and sulfuratom; wherein each n is a number independently selected from zero tosix, inclusive;

wherein each of R¹⁴ through R²⁶ is independently selected from hydrido,alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyland phenyl;

wherein each of R³ through R¹¹ is independently selected from hydrido,hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, alkoxy, phenyl, benzoyl,phenoxy, alkoxyalkyl, acetyl, alkoxycarbonyl, alkenyl, cyano, nitro,carboxyl, alkylthio and mercapto;

and wherein each of R³ through R¹¹ may be further independently selectedfrom acidic moieties consisting of CO₂ H, CO₂ CH₃, SH, CH₂ SH, C₂ H₄ SH,PO₃ H₂, NHSO₂ CF₃, NHSO₂ C₆ F₅, SO₃ H, CONHNH₂, CONHNHSO₂ CF₃, CONHOCH₃,CONHOC₂ H₅, CONHCF₃, OH, CH₂ OH, C₂ H₄ OH, OPO₃ H₂, OSO₃ H, ##STR32##wherein each of R⁴², R⁴³ and R⁴⁴ is independently selected from H, Cl,CN, NO₂, CF₃, C₂ F₅, C₃ F₇, CHF₂, CH₂ F, CO₂ CH₃, CO₂ C₂ H₅, SO₂ CH₃,SO₂ CF₃ and SO₂ C₆ F₅ ; wherein Z is selected from O, S, NR⁴⁵ and CH₂ ;wherein R⁴⁵ is selected from hydrido, CH₃ and CH₂ C₆ H₅ ; and whereinsaid acidic moiety may be a heterocyclic acidic group attached at anytwo adjacent positions of R³ through R¹¹ so as to form a fused ringsystem with one of the phenyl rings of the biphenyl moiety of Formula I,said biphenyl fused ring system selected from ##STR33## and the esters,amides and salts of said acidic moieties; or a tautomer thereof or apharmaceutically-acceptable salt thereof.

A class of compounds of particular interest consists of those compoundsof Formula I wherein m is one; wherein R¹ is selected from methyl,ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl,n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl,cyclohexylmethyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and2-hydroxybutyl; wherein R² is selected from C₄ H₉ (n), CH₃ CH₂ CH═CH, C₃H₇ (n), SC₃ H₇, ##STR34## amino, aminomethyl, aminoethyl, aminopropyl,acetyl, CH₂ OH, CH₂ OCOCH₃, CH₂ Cl, Cl, CH₂ OCH₃, CH₂ OCH(CH₃)₂, I, CHO,##STR35## --CH₂ NHCO₂ CH₂ (CH₃)₂, --CH₂ NHCO₂ C₄ H₉, CH₂ NHCO₂-adamantyl, --CH₂ NHCO₂ -(1-napthyl), --CH₂ NHCONHCH₃, --CH₂ NHCONHC₂H₅, --CH₂ NHCONHC₃ H₇, --CH₂ NHCONHC₄ H₉, --CH₂ NHCONHCH(CH₃)₂, --CH₂NHCONH(1-napthyl ), --CH₂ NHCONH(1-adamantyl), CO₂ H, ##STR36## H, Cl,NO₂, CF₃, CH₂ OH, Br, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl,sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl,cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl,1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxypentyl, hydroxyalkyl,halo, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl,2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl,1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl,cyclohexylmethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl,1-butynyl, 2-butynyl, 3-butynyl and difluoromethyl; wherein each of R³through R¹¹ is hydrido with the proviso that at least one of R⁵, R⁶, R⁸and R⁹ is an acidic group selected from CO₂ H, SH, PO₃ H₂, SO₃ H,CONHNH₂, CONHNHSO₂ CF₃, OH, ##STR37## wherein each of R⁴² and R⁴³ isindependently selected from chloro, cyano, nitro, trifluoromethyl,methoxycarbonyl and trifluoromethylsulfonyl;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

A class of compounds of more particular interest consists of thosecompounds of Formula I wherein m is one; wherein R¹ is selected frommethyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, phenyl, benzyl,phenethyl, cyclohexyl, cyclohexylmethyl, 2-butenyl, 3-butenyl,2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R² is selected fromethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl,tert-butyl, n-pentyl, neopentyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl,1-oxopentyl 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl,2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl,1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl,cyclohexylmethyl, cyclohexanoyl, acetyl, 1-butenyl, 2-butenyl,3-butenyl, 1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio;wherein each of R³ through R¹¹ is hydrido with the proviso that at leastone of R⁵, R⁶, R⁸ and R⁹ is an acidic group selected from CO₂ H, SH, PO₃H₂, SO₃ H, CONHNH₂, CONHNHSO₂ CF₃, OH, ##STR38## wherein each of R⁴² andR⁴³ is independently selected from chloro, cyano, nitro,trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl;

or a tautomer thereof or a pharmaceutically-acceptable salt thereof.

A subclass of compounds of Formula I which is of even more particularinterest consists of those compounds of Formula II ##STR39## wherein mis one; wherein R¹ is selected from methyl, ethyl, n-propyl, isopropyl,n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl,neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl,2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; whereinR² is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,isobutyl, 4-methylbutyl, n-pentyl, 1-oxo-2-phenylethyl,1-oxo-2-cyclohexylethyl, 1,1-difluoro-2-phenylethyl,1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl,1,1-difluoro-3-cyclohexylpropyl, 1-dimethoxybutyl, 1,1-difluoroethyl,1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl,2-phenylethyl, 1,1-difluoro-3-phenylpropyl, cyclohexylmethyl,cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl,3-butynyl, propylthio and butylthio; wherein R⁵ is an acidic groupselected from CO₂ H and ##STR40## or a tautomer thereof or apharmaceutically-acceptable salt thereof.

A family of specific compounds of particular interest within Formula IIconsists of the following compounds:

2-[6-[(1-propyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoic acid;

2-[6-[(1-propyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1,3-dipropyl-1H-1,2,4-triazol-5-yl) methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-propyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-propyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-propyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-propyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-propyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-propyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-propyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-propyl-3-cyclohexyl-1H-1,2,4-triazol-5yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-propyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-propyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-propyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-propyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-propyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-propyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-propyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-propyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-propyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-propyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-propyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-propyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-propyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-butyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-butyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-butyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-butyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-butyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-butyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-pentyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-pentyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-pentyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-pentyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-pentyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-pentyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-pentyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-pentyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1,3-dipentyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-pentyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-pentyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-pentyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-pentyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-pentyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-pentyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-pentyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-pentyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-pentyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[(1-pentyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-pentyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-pentyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-pentyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-pentyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-pentyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-pentyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-pentyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

2-[6-[[1-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]benzoicacid;

5-[2-[6-[(1-propyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-propyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1,3-dipropyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-propyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-propyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-propyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-propyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-propyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-propyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-propyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-propyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-propyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-propyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-propyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-propyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-propyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-propyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-propyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-propyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-propyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-propyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-propyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-propyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-propyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-butyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-butyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-butyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-butyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-pentyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-pentyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-pentyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-pentyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-pentyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-pentyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-pentyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-pentyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1,3-di-pentyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-pentyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-pentyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-pentyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-pentyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-pentyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-pentyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-pentyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-pentyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-pentyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-pentyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-pentyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-pentyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-pentyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-pentyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-pentyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-pentyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-pentyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole;and

5-[2-[6-[[1-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]-3-pyridinyl]phenyl]-1H-tetrazole.

A family of specific compounds of more particular interest withinFormula II consists of the following compounds:

5-[2-[6-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[6-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;and

5-[2-[6-[(1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole.

Another subclass of compounds of Formula I which is of even moreparticular interest consists of those compounds of Formula III ##STR41##wherein m is one; wherein R¹ is selected from methyl, ethyl, n-propyl,isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl,n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl,cyclohexylmethyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and2-hydroxybutyl; wherein R² is selected from ethyl, n-propyl, isopropyl,n-butyl, sec-butyl, isobutyl, 4-methylbutyl, n-pentyl,1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl,2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl,1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl,cyclohexylmethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl,1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein R⁵ isan acidic group selected from CO₂ H and ##STR42## or a tautomer thereofor a pharmaceutically-acceptable salt thereof.

A family of specific compounds of particular interest within Formula IIIconsists of the following compounds:

2-[5-[(1-propyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-propyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]-2pyridinyl]benzoicacid;

2-[5-[(1,3-dipropyl-1H-1,2,4-triazol-5-yl)methyl]-2pyridinyl]benzoicacid;

2-[5-[(1-propyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-propyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]-2pyridinyl]benzoicacid;

2-[5-[(1-propyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-propyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-propyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-propyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-propyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-propyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-propyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-propyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-propyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-propyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[[l-propyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-propyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-propyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-propyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-propyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-propyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-propyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-propyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-propyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-butyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-butyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-butyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-butyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-butyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-butyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-pentyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-pentyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-pentyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-pentyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-pentyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-pentyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-pentyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-pentyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1,3-dipentyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-pentyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-pentyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-pentyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-pentyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-pentyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-pentyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-pentyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-pentyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-pentyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[(1-pentyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-pentyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-pentyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-pentyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-pentyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-pentyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-pentyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-pentyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

2-[5-[[1-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]benzoicacid;

5-[2-[5-[(1-propyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-propyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1,3-dipropyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-propyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-propyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-propyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-propyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-propyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-propyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-propyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-propyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-propyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-propyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-propyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-propyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-propyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-propyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-propyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-propyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-propyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-propyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-propyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-propyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-propyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]--pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-butyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-butyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-butyl-3-(1,l-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-butyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-butyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-pentyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-pentyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-pentyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-pentyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-pentyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-pentyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-pentyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-pentyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1,3-dipentyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-pentyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-pentyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-pentyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-pentyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-pentyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-pentyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-pentyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-pentyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-pentyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-pentyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-pentyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-pentyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-pentyl-3-(1,1-methoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-pentyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-pentyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-pentyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-pentyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;and

5-[2-[5-[[1-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole.

A family of specific compounds of more particular interest withinFormula III consists of the following compounds:

5-[2-[5-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;

5-[2-[5-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;and

5-[2-[5-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole.

Another subclass of compounds of Formula I which is of even moreparticular interest consists of those compounds of Formula IV ##STR43##wherein m is one; wherein R¹ is selected from methyl, ethyl, n-propyl,isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl,n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl,cyclohexylmethyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and2-hydroxybutyl; wherein R² is selected from ethyl, n-propyl, isopropyl,n-butyl, sec-butyl, isobutyl, 4-methylbutyl, n-pentyl,1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl,2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl,1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl,cyclohexylmethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl,1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein R⁵ isan acidic group selected from CO₂ H and ##STR44## or a tautomer thereofor a pharmaceutically-acceptable salt thereof.

A family of specific compounds of particular interest within Formula IVconsists of the following compounds:

2-[4-[(1-propyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-propyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1,3-dipropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-propyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-propyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-propyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-propyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-propyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-propyl-3-pentyl-1-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-propyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-propyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-propyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-propyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-propyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-propyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-propyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-propyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-propyl-3-(1-oxo-2-cyclohexyethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-propyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-propyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-propyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-propyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-propyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[i-propyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[l-propyl-3-(l,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-butyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-butyl-3-(1-oxo-2-cyclohexyethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-butyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-butyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-butyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-butyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-pentyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-pentyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-pentyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-pentyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-pentyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-pentyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-pentyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-pentyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1,3-dipentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-pentyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-pentyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-pentyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-pentyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-pentyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-pentyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-pentyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-pentyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-pentyl-3-(1-oxo-2-cyclohexyethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[(1-pentyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-pentyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-pentyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-pentyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-pentyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-pentyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-pentyl-3-(t-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-pentyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

2-[4-[[1-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

5-[2-[4-[(1-propyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-propyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1,3-dipropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-propyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-propyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-propyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-propyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-propyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-propyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-propyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-propyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-propyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-propyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-propyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-propyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-propyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-propyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-propyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-propyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-propyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-propyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-propyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-propyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-propyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-butyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-butyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-butyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-butyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-pentyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-pentyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-pentyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-pentyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-pentyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-pentyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-pentyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-pentyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1,3-dipentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-pentyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-pentyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-pentyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-pentyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-pentyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-pentyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-pentyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-pentyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-pentyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-pentyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-pentyl-3-(i-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-pentyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-pentyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-pentyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-pentyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-pentyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-pentyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;and

5-[2-[4-[[1-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole.

A family of specific compounds of more particular interest withinFormula IV consists of

5-[2-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[2-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;and

5-[2-[4-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole.

Another subclass of compounds of Formula I which is of even moreparticular interest consists of those compounds of Formula V ##STR45##wherein m is one; wherein R¹ is selected from methyl, ethyl, n-propyl,isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl,n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl,cyclohexylmethyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and2-hydroxybutyl; wherein R² is selected from ethyl, n-propyl, isopropyl,n-butyl, sec-butyl, isobutyl, 4-methylbutyl, n-pentyl,1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl,2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl,1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl,cyclohexylmethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl,1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein R⁵ isan acidic group selected from CO₂ H and ##STR46## or a tautomer thereofor a pharmaceutically-acceptable salt thereof.

A family of specific compounds of particular interest within Formula Vconsists of the following compounds:

3-[4-[(1-propyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1,3-dipropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[l-butyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[i-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-propyl-1H-1,2,4-triazol-5)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1,3-dipentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-pentyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-pentyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-pentyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-pentyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-pentyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-pentyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-pentyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-pentyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-pentyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-pentyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

3-[4-[[1-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinecarboxylicacid;

5-[3-[4-[(1-propyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1,3-dipropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1,3-dipentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;and

5-[3-[4-[[t-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole.

A family of specific compounds of more particular interest withinFormula V consists of the following compounds:

5-[3-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;and

5-[3-[4-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole.

Another subclass of compounds of Formula I which is of even moreparticular interest consists of those compounds of Formula VI ##STR47##wherein m is one; wherein R¹ is selected from methyl, ethyl, n-propyl,isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl,n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl,cyclohexylmethyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and2-hydroxybutyl; wherein R² is selected from ethyl, n-propyl, isopropyl,n-butyl, sec-butyl, isobutyl, 4-methylbutyl, n-pentyl,1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl,2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl,1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl,cyclohexylmethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl,1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein R⁵ isan acidic group selected from CO₂ H and ##STR48## or a tautomer thereofor a pharmaceutically-acceptable salt thereof.

A family of specific compounds of particular interest within Formula VIconsists of the following compounds:

4-[4-[(1-propyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1,3-dipropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-propyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-propyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-propyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-propyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-propyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-propyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-propyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-propyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-propyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-propyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-propyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-propyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-propyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-propyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-propyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-propyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-propyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-propyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-propyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-propyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-propyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid

4-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-butyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-butyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-butyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-butyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-butyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-butyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-pentyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-pentyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-pentyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-pentyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-pentyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-pentyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-pentyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-pentyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1,3-dipentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-pentyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-pentyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-pentyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-pentyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-pentyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-pentyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-pentyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-pentyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-pentyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[(1-pentyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-pentyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-pentyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-pentyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-pentyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-pentyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-pentyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-pentyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

4-[4-[[1-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinecarboxylicacid;

5-[4-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-propyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-propyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1,3-dipropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-propyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-propyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-propyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-propyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-propyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-propyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-propyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-propyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-propyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-propyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-propyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-propyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-propyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-propyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-propyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-propyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-propyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-propyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-propyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-propyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-propyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-butyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-butyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-butyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-butyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-pentyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-pentyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-pentyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-pentyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-pentyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-pentyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-pentyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-pentyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1,3-dipentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-pentyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-pentyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-pentyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-pentyl-3-(2-cyclohexylethyl)-1H-1,2,4triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-pentyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-pentyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-pentyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-pentyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-pentyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-pentyl-3-benzoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-pentyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-pentyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-pentyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-pentyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-pentyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-pentyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-pentyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

A family of specific compounds of more particular interest withinFormula VI consists of the following compounds:

5-[4-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;

5-[4-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;and

5-[4-[4-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole.

Another subclass of compounds of Formula I which is of even moreparticular interest consists of those compounds of Formula VII ##STR49##wherein m is one; wherein R¹ is selected from methyl, ethyl, n-propyl,isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl,n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl,cyclohexylmethyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and2-hydroxybutyl; wherein R² is selected from ethyl, n-propyl, isopropyl,n-butyl, sec-butyl, isobutyl, 4-methylbutyl, n-pentyl,1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl,2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl,1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl,cyclohexylmethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl,1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein R⁵ isan acidic group selected from CO₂ H and ##STR50## or a tautomer thereofor a pharmaceutically-acceptable salt thereof.

A family of specific compounds of particular interest within Formula VIIconsists of the following compounds:

3-[4-[(1-propyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1,3-di-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-propyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-benzoyl-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-propyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-butyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-benzoyl-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-butyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-isopropyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-butyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinecarboxylic acid;

3-[4-[(1-pentyl-3-secbutyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinecarboxylic acid;

3-[4-[(1-pentyl-3-isobutyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinecarboxylic acid;

3-[4-[(1-pentyl-3-butyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinecarboxylic acid;

3-[4-[(1-pentyl-3-tertbutyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinecarboxylic acid;

3-[4-[(1,3-dipentyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-isopentyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-cyclohexyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinecarboxylic acid;

3-[4-[(1-pentyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinecarboxylic acid;

3-[4-[[1-pentyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylis acid;

3-[4-[(1-pentyl-3-phenyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[(1-pentyl-3-phenylmethyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-pentyl-3-(2-phenylethyl) -1H-l, 2,4-triazol-5yl]methyl]phenyl]-2 -pyridinecarboxylic acid;

3-[4-[(1-pentyl-3-cyclohexanoyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinecarboxylic acid;

3-[4-[[1-pentyl-3-(1-oxo-2-cyclohexylethyl )-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylic acid;

3-[4-[[1-pentyl-3-benzoyl-1H-1,2,4-triazol-5yl]methyl]phenyl]-2-pyridinecarboxylic acid;

3-[4-[[1-pentyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylic acid;

3-[4-[[1-pentyl-3-(1, 1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylic acid;

3-[4-[[1-pentyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2 -pyridinecarboxylic acid;

3-[4-[[1-pentyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2 -pyridinecarboxylic acid;

3-[4-[[1-pentyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5yl]methyl]phenyl]-2-pyridinecarboxylic acid;

3-[4-[[1-pentyl-3-(1-oxobutyl) -1H-1,2,4-triazol-5yl]methyl]phenyl]-2-pyridinecarboxylic acid;

3-[4-[[1-pentyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5yl]methyl]phenyl]-2-pyridinecarboxylicacid;

3-[4-[[1-pentyl-3-(1,1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinecarboxylicacid;

5-[3-[4-[(1-propyl-3-methyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-ethyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1,3-dipropyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-isopropyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-butyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-secbutyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-isobutyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-tertbutyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-pentyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-isopentyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-cyclohexyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1 -propyl-3-phenyl-1H-1, 2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-phenylmethyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-cyclohexanoyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5- [3- [4-[[1 -propyl-3-(1-oxo-2-cyclohexylethyl )-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-propyl-3-benzoyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1 -propyl-3-(1-oxo-2-phenylethyl )-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2 -pyridinyl]-1H-tetrazole;

5-[3-[4-[[1 -propyl-3-(1, 1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1 -propyl-3-(1,1 -dimethoxybutyl )-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(1,1-dimethoxypentyl )-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-propyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1 -propyl-3-(1 -difluorobutyl)-1H-1,2,4-triazol5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1, 3-dibutyl-1H-1,2,4-triazol-5yl) methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(2-phenylethyl) -1H-l, 2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-cyclohexanoyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-benzoyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1,1-dimethoxyentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-methyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-butyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1,3-dipentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-phenyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-cyclohexanoyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(1-oxo-2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-pentyl-3-benzoyl-1H-1,2,4-triazol-5yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(1-oxo-2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(1,1-dimethoxypropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(1,1-dimethoxybutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(1,1-dimethoxypentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(1-oxopropyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(1-oxobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-pentyl-3-(1-oxopentyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole; and

5-[3-[4-[[1-pentyl-3-(1-difluorobutyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1Hetrazole.

A family of specific compounds of more particular interest withinFormula VII consists of the following compounds:

5-[3-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;

5-[3-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;and

5-[3-[4-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole.

The term "hydrido" denotes a single hydrogen atom (H). This hydridogroup may be attached, for example, to an oxygen atom to form a hydroxylgroup; or, as another example, one hydrido group may be attached to acarbon atom to form a ##STR51## or, as another example, two hydridogroups may be attached to a carbon atom to form a --CH₂ -- group. Wherethe term "alkyl" is used, either alone or within other terms such as"haloalkyl" and "hydroxyalkyl", the term "alkyl" embraces linear orbranched radicals having one to about twenty carbon atoms or,preferably, one to about twelve carbon atoms. More preferred alkylradicals are "lower alkyl" radicals having one to about ten carbonatoms. Most preferred are lower alkyl radicals having one to about fivecarbon atoms. The term "cycloalkyl" embraces cyclic radicals havingthree to about ten ring carbon atoms, preferably three to about sixcarbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl andcyclohexyl. The term "haloalkyl" embraces radicals wherein any one ormore of the alkyl carbon atoms is substituted with one or more halogroups, preferably selected from bromo, chloro and fluoro. Specificallyembraced by the term "haloalkyl" are monohaloalkyl, dihaloalkyl andpolyhaloalkyl groups. A monohaloalkyl group, for example, may haveeither a bromo, a chloro, or a fluoro atom within the group. Dihaloalkyland polyhaloalkyl groups may be substituted with two or more of the samehalo groups, or may have a combination of different halo groups. Adihaloalkyl group, for example, may have two fluoro atoms, such asdifluoromethyl and difluorobutyl groups, or two chloro atoms, such as adichloromethyl group, or one fluoro atom and one chloro atom, such as afluoro-chloromethyl group. Examples of a polyhaloalkyl aretrifluoromethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl, perfluoroethyland 2,2,3,3-tetrafluoropropyl groups. The term "difluoroalkyl" embracesalkyl groups having two fluoro atoms substituted on any one or two ofthe alkyl group carbon atoms. The terms "alkylol" and "hydroxyalkyl"embrace linear or branched alkyl groups having one to about ten carbonatoms any one of which may be substituted with one or more hydroxylgroups. The term "alkenyl" embraces linear or branched radicals havingtwo to about twenty carbon atoms, preferably three to about ten carbonatoms, and containing at least one carbon-carbon double bond, whichcarbon-carbon double bond may have either cis or trans geometry withinthe alkenyl moiety. The term "alkynyl" embraces linear or branchedradicals having two to about twenty carbon atoms, preferably two toabout ten carbon atoms, and containing at least one carbon-carbon triplebond. The term "cycloalkenyl" embraces cyclic radicals having three toabout ten ring carbon atoms including one or more double bonds involvingadjacent ring carbons. The terms "alkoxy" and "alkoxyalkyl" embracelinear or branched oxy-containing radicals each having alkyl portions ofone to about ten carbon atoms, such as methoxy group. The term"alkoxyalkyl" also embraces alkyl radicals having two or more alkoxygroups attached to the alkyl radical, that is, to form monoalkoxyalkyland dialkoxyalkyl groups. The "alkoxy" or "alkoxyalkyl" radicals may befurther substituted with one or more halo atoms, such as fluoro, chloroor bromo, to provide haloalkoxy or haloalkoxyalkyl groups. The term"alkylthio" embraces radicals containing a linear or branched alkylgroup, of one to about ten carbon atoms attached to a divalent sulfuratom, such as a methythio group. Preferred aryl groups are thoseconsisting of one, two, or three benzene rings. The term "aryl" embracesaromatic radicals such as phenyl, naphthyl and biphenyl. The term"aralkyl" embraces aryl-substituted alkyl radicals such as benzyl,diphenylmethyl, triphenylmethyl, phenylethyl, phenylbutyl anddiphenylethyl. The terms "benzyl" and "phenylmethyl" areinterchangeable. The terms "aryloxy" and " arylthio" denote radicalrespectively, aryl groups having an oxygen or sulfur atom through whichthe radical is attached to a nucleus, examples of which are phenoxy andphenylthio. The terms "sulfinyl" and "sulfonyl", whether used alone orlinked to other terms, denotes respectively divalent radicals SO andSO₂. The term "aralkoxy", alone or within another term, embraces an arylgroup attached to an alkoxy group to form, for example, benzyloxy. Theterm "acyl" whether used alone, or within a term such as acyloxy,denotes a radical provided by the residue after removal of hydroxyl froman organic acid, examples of such radical being acetyl and benzoyl."Lower alkanoyl" is an example of a more prefered sub-class of acyl. Theterm "amido" denotes a radical consisting of nitrogen atom attached to acarbonyl group, which radical may be further substituted in the mannerdescribed herein. The amido radical can be attached to the nucleus of acompound of the invention through the carbonyl moiety or through thenitrogen atom of the amido radical. The term "alkenylalkyl" denotes aradical having a double-bond unsaturation site between two carbons, andwhich radical may consist of only two carbons or may be furthersubstituted with alkyl groups which may optionally contain additionaldouble-bond unsaturation. The term "heteroaryl" embraces aromatic ringsystems containing one or two hetero atoms selected from oxygen,nitrogen and sulfur in a ring system having five or six ring members,examples of which are thienyl, furanyl, pyridinyl, thiazolyl, pyrimidyland isoxazolyl. Such heteroaryl may be attached as a substituent througha carbon atom of the heteroaryl ring system, or may be attached througha carbon atom of a moiety substituted on a heteroaryl ring-member carbonatom, for example, through the methylene substituent of imidazolemethylmoiety. Also, such heteroaryl may be attached through a ring nitrogenatom as long as aromaticity of the heteroaryl moiety is preserved afterattachment. For any of the foregoing defined radicals, preferredradicals are those containing from one to about ten carbon atoms.

Specific examples of alkyl groups are methyl, ethyl, n-propyl,isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl,isopentyl, methylbutyl, dimethylbutyl and neopentyl. Typical alkenyl andalkynyl groups may have one unsaturated bond, such as an allyl group, ormay have a plurality of unsaturated bonds, with such plurality of bondseither adjacent, such as allene-type structures, or in conjugation, orseparated by several saturated carbons.

Compounds of Formula I have been found to inhibit the action ofangiotensin II in mammals. Angiotensin Ii is a potent vasoconstrictorand participates in the formation of aldosterone which regulates sodiumand water balance in meals. Thus, compounds of Formula I aretherapeutically useful in methods for treating hypertension byadministering to a hypertensive patient a therapeutically-effectiveamount of a compound of Formula I. The phrase "hypertensive patient"means, in this context, a mammalian subject suffering from or afflictedby the effects of hypertension or susceptible to a hypertensivecondition if not treated to prevent or control such hypertension.

Also included in the family of compounds of Formula I are isomeric formsincluding diastereoisomers, regioisomers and thepharmaceutically-acceptable salts thereof. The term"pharmaceutically-acceptable salts" embraces salts commonly used to formalkali metal salts and to form addition salts of free acids or freebases. The nature of the salt is not critical, provided that it ispharmaceutically-acceptable. Suitable pharmaceutically-acceptable acidaddition salts of compounds of Formula I may be prepared from aninorganic acid or from an organic acid. Examples of such inorganic acidsare hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuricand phosphoric acid. Appropriate organic acids may be selected fromaliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic,carboxylic and sulfonic classes of organic acids, example of which areformic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic,tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic,aspartic, glutamic, benzoic, anthranilic, p-hydroxybenzoic, sailcyclic,phenylacetic, mandelic, embonic (pamoic), methansulfonic,ethanesulfonic, 2-hydroxyethanesulfonic, pantothenic, benzenesulfonic,toluenesulfonic, sulfanilic, mesylic, cyclohexylaminosulfonic, stearic,algenic, D-hydroxybutyric, malonic, galactaric and galacturonic acid.Suitable pharmaceutically-acceptable base addition salts of compounds ofFormula I include metallic salts made from aluminium, calcium, lithium,magnesium, potassium, sodium and zinc or organic salts made fromN,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine,ethylenediamine, meglumine (N-methylglucamine) and procaine. All ofthese salts may be prepared by conventional means from the correspondingcompound of Formula I by reacting, for example, the appropriate acid orbase with the compound of Formula I.

General Synthetic Procedures

The compounds of the invention can be synthesized according to thefollowing procedures of Schemes I-XI, wherein the R substituents are asdefined for Formula I, above, except where further noted. ##STR52##

Synthetic Scheme I shows the preparation of the boronic acid 1 where R⁵equals N-tertbutyl-N-methylcarboxamide. In step 1, benzoic acid istreated with thionyl chloride to give the corresponding acid chloridewhich is subsequently reacted with N-tertbutyl-Nmethylamine to giveN-tertbutyl-N-methylbenzamide. In step 2, the amide is ortho-metalatedand subsequently reacted with trimethyl borate. The free boronic acid Iis produced on hydroylsis. ##STR53##

Synthetic Scheme II shows the preparation of the boronic acid 1 where R⁵equals N-triphenylmethyl-1H-tetrazole. In step 1, 2-bromobenzonitrile(Aldrich) is reacted with trimethyltin azide to give the correspondingtetrazole. In step 2, the tetrazole is reacted with triphenylmethylchloride in the presence of triethylamine to give the protectedbromophenyltetrazole. In step 3, halogen-metal interchange withn-butyllithium generates the corresponding ortho-lithiated species whichis reacted with trimethyl borate. The free boronic acid 1 is produced onhydrolysis. ##STR54##

Synthetic Scheme III shows the regiospecific preparation of N²-monoalkylsubstituted hydrazides 2. In step 1, hydrazine is reacted witha methyl ester to give the corresponding unsubstituted hydrazide. Instep 2, the hydrazide is reacted with the appropriate aldehyde to givethe corresponding imine. In step 3, the imine is reduced with sodiumborohydride to give the desired N2-substituted hydrazide 2. ##STR55##

Synthetic Scheme IV shows the preparation of5-(2-pyridinyl)methyl-1H-1,2,4-triazoles a from 2-picoline (Aldrich). Instep 1, 2-picoline is reacted with bromine in the presence of a largeexcess of aluminum chloride at elevated temperatures to give5-bromo-2-picoline (4). In step 2, 4 a is reacted with NBS to give the2-pyridinylmethyl bromide 5. In step 3, 5 is reacted with potassiumcyanide to give the 2-pyridinylacetonitrile 6. In step 4, 6 is reactedwith hydrogen chloride and ethanol to give the imidate esterhydrochloride which is subsequently converted to the free imidate ester7 on treatment with ammonia at low temperatures. In step 5, the imidate7 is reacted with hydrazide 2 (Scheme III) to give the bromotriazole 8.In step 6, the bromotriazole 8 is reacted with the boronic acid 1(Scheme II) in the presence of a palladium zero catalyst via a Snieckuscoupling [see M. J. Sharp and V. Snieckus, Tetrahedron Lett., 5997(1985)] to give the angiotensin II antagonists 3 of the invention.##STR56##

Synthetic Scheme V shows the preparation of5-(3-pyridinyl)methyl-1H-1,2,4-triazoles a from 2-amino-5-picoline(Aldrich). In step 1, 2-amino-5-picoline is reacted with bromine in thepresence of hydrobromic acid and sodium nitrite at 0° C. to give2-bromo-5-picoline (10). In step 2, 10 is reacted with NBS to give the3-pyridinylmethyl bromide 11. In step 3, 11 is reacted with potassiumcyanide to give the 3-pyridinylacetonitrile 12. In step 4, 12 is reactedwith hydrogen chloride and ethanol to give the imidate esterhydrochloride which is subsequently converted to the free imidate ester13 on treatment with ammonia at low temperatures. In step 5, the imidate13 is reacted with the hydrazide 2 (Scheme III) to give thebromotriazole 14. In step 6, the bromotriazole 14 is reacted with theboronic acid 1 (Scheme II) in the presence of a palladium zero catalystvia a Snieckus coupling [see M. J. Sharp and V. Snieckus, TetrahedronLett., 5997 (1985)] to give the angiotensin II antagonists 9 of thisinvention. ##STR57##

Synthetic Scheme VI shows the preparation of the 4-bromopyridinecoupling reagent 15 [R⁵ =CON(CH₃)C(CH₃)₃ ] and the 2-bromopyridinecoupling reagent 16 [R⁵ =CON(CH₃)C(CH₃)₃ ] from nicotinic acid. In step1, N-tertbuty-N-methylnicotinamide is prepared from nicotinoyl chlorideand N-tertbutyl-N-methylamine. In step 2, ortho-metalalion withsec-butyllithium gives a mixture of regioanions which are reacted withtrimethylsilyl chloride; subsequent conversion to the correspondingbromides on treatment with bromine in acetic acid and separation of theregioisomers by chromatography provides 15 and 16. ##STR58##

Synthetic Scheme VII shows the preparation of the 3-bromopyridinecoupling reagent 17 [R⁵ =CON(CH₃)C(CH₃)₃ ] from isonicotinic acid. Instep 1, N-tertbutyl-N-methylisonicotinamide is prepared fromisonicotinoyl chloride and N-tertbutyl-N-methylamine. In step 2,reaction with sec-butyllithium gives the ortho-lithiated species whichis reacted with trimethylsilyl chloride; subsequent conversion to thecorresponding bromide on treatment with bromine in acetic acid provides17. ##STR59##

118 C-2653

Synthetic Scheme VIII shows the preparation of the 3-bromopyridinecoupling reagent 18 [R⁵ =CON(CH₃)C(CH₃)₃ ] from picolinic acid. In step1, N-tertbutyl-N-methylpicolinamide is prepared from picolinoyl chlorideand N-tertbutyl-N-methylamine. In step 2, reaction withsec-butyllithiumgives the ortho-lithiated species which is reacted withtrimethylsilyl chloride; subsequent conversion to the correspondingbromide on treatment with bromine in acetic acid provides 18. ##STR60##

Synthetic Scheme IX shows the preparation of the triazole boronic acidcoupling reagent 19 from 4-bromophenylacetonitrile (Aldrich). In step 1,reaction with hydrogen chloride and ethanol in ether at 0° C. producesthe imidate ester hydrochloride which is subsequently converted to thefree imidate ester 20 on treatment with ammonia at low temperatures. Instep 2, the imidate ester 20 is reacted with the hydrazide 2 (SchemeIII) to give the bromotriazole 21. In step 3, halogen-metal interchangewith n-butyllithium generates the corresponding lithiated species whichis reacted with trimethyl borate. The free triazole boronic acidcoupling reagent 19 is produced on hydrolysis. ##STR61##

Synthetic Scheme X shows the preparation of 5-(pyridinylphenyl)methyl-1H-1,2,4-triazoles 22, 23, 24 and 25 from thecommon triazole boronic acid 19 (Scheme IX) and the corresponding bromocoupling reagents 18 (Scheme VIII), 15 (Scheme VI), 17 (Scheme VII), and16 (Scheme VI), respectively. The boronic acid 19 is reacted with thebromo coupling reagents 18, 15, 17 and 18 in the presence of a palladiumzero catalyst via a Snieckus coupling [see M. J. Sharp and V. Snieckus,Tetrahedron Lett., 5997 (1985)] to give the angiotensin II antagonists22, 23, 24, and 25, respectively, of this invention. ##STR62##

Synthetic Scheme XI shows the preparation of carboxylic acid analogs 26and 1H-tetrazole analogs 27 from analogs which have R⁵ =CON(CH₃)C(CH₃)₃.In step 1, the N-tertbutyl-N-methylamide analog 28 is reacted withtrifluoroacetic acid at reflux to give the N-methylamide 29. In step 2,the N-methylamide 29 is reacted with sodium nitrite in aceticanhydride/acetic acid at 0° C. to give the correspondingN-methyl-N-nitrosoamide 30. In step 3, the N-methyl-N-nitrosoamide 30 ishydrolyzed in base to give the corresponding carboxylic acid angiotensinII antagonists of this invention. In step 4, the acid analog 26 isreacted with oxalyl chloride and subsequently with anhydrous ammonia togive the primary amide 31. In step 5, the amide 31 is reacted withtriphenylphosphine in carbon tetrachloride at 50° C. to give thecorresponding nitrile 32. In step 6, the nitrile 32 is reacted withtrimethyltin azide in xylene at reflux to provide the 1H-tetrazoleangiotensin II antagonists of this invention.

The following Example is a detailed description of the methods ofpreparation of compounds of Formula I. This detailed preparation fallswithin the scope of, and serves to exemplify, the above describedGeneral Synthetic Procedures which form part of the invention. ThisExample is presented for illustrative purposes only and is not intendedas a restriction on the scope of the invention. All parts are by weightunless otherwise indicated.

EXAMPLE 1 ##STR63##5-[2-[5-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazoleStep 1; Preparation of 2-(N-triphenylmethyltetrazol-5-yl)phenylboronicacid

A 64 g (350 mmol) sample of 2-bromobenzonitrile (Aldrich) was dissolvedin 650 mL of xylene and treated with 22.75 g (350 mmol) of sodium azideand 95 mL (350 mmol) of tributyltin chloride at reflux for 48 h. Thereaction was filtered; the filtrate was treated with 50 mL of anhydroustetrahydrofuran (THF) and 20 g (550 mmol) of hydrogen chloride. Thereaction was stirred for 2 h; filtration gave 59.6 g (76%) of5-(2-bromophenyl)-1H-tetrazole: mp 178°-180° C.; NMR (DMSO-d₆)δ7.50-7.64 (m, 2H), 7.67-7.74 (m, 1H), 7.83-7.91 (m, 1H). A 41.8 g (187mmol) sample of this material was dissolved in 650 mL of methylenechloride and treated with 55.5 g (193 mmol) of triphenylmethyl chlorideand 30 mL (220 mmol) of anhydrous triethylamine. The reaction wasallowed to stir overnight at reflux, cooled to ambient temperature,washed with water, dried (MgSO₄), and concentrated in vacuo.Recrystallization from toluene/hexane gave 80.7 g (92%) ofN-triphenylmethyl-5-(2-bromophenyl)-1H-tetrazole: mp 160°-162° C.; NMR(CDCl₃) δ 7.14-7.21 (m, 6H), 7.26-7.45 (m, 11H), 7.70 (dd, J=8 and 1.5Hz, 1H), 7.89 (dd, J=7.5 and 2 Hz, 1H). A 34.05 g (73.0 mmol) sample ofthis material was dissolved in 1700 mL of THF under a nitrogenatmosphere and treated with 73 mmol of n-butyllithium in hexane. Thereaction was allowed to stir for 17 min and then was treated with 24.9mL (220 mmol) of trimethyl borate. The reaction was allowed to come toambient temperature overnight while stirring, quenched with 10 mL ofmethanol, and concentrated in vacuo. The residue was dissolved in 1MNaOH and extracted with toluene to remove any unreacted startingmaterial. The pH was adjusted to 6 with 6M HCl and the product extractedwith toluene and dried (MgSO₄). Hexane was added and the solution keptin the freezer overnight. Filtration provided 31.3 g (99%) of2-(N-triphenylmethyl-tetrazol-5-yl) phenylboronic acid: NMR (CDCl₃)δ7.13-7.21 (m, 7H), 7.33-7.42 (m, 8H), 7.49-7.55 (m, 2H), 8.15-8.19 (m,1H), 8.21-8.26 (m, 1H).

Step 2: Preparation of N² -butyl valeric acid hydrazide

To a solution of 400 g (3.44 mol) of valeric acid hydrazide (LancasterSynthesis) in 3000 mL of dichloromethane under a nitrogen atmosphere,was added 250 g (2 mol) of anhydrous magnesium sulfate and 310 g (3.88mol) of butyraldehyde. The reaction was stirred at ambient temperaturefor 17 h, filtered, and concentrated in vacuo providing 613 g of nearlycolorless solid: mp 66.5°-68.0° C.; NMR (CDCl₃) δ 0.97 (t, J=7Hz, 3H),0.92 (t, J=7Hz, 3H), 1.31-1.46 (m, 2H), 1.48-1.73 (m, 4H), 2.19-2.28 (m,2H), 2.62 (t, J=7Hz, 2H), 7.14 (t, J=6Hz, 1H), 9.18 (br s, 1H). Thismaterial was dissolved in 3000 mL of ethanol and cooled to 0° C. in anice bath prior to the addition of 130.1 g (3.44 mol) of sodiumborohydride. The reaction was maintained at 0° C. for 3 h and thenallowd to slowly warm to ambient temperature overnight. The volatileswere removed in vacuo and the residue dissolved in 1500 mL of water andconninuousiy extracted with ether/dichloromethane (1:1) overnight. Theextracts were dried (Na₂ SO₄) and concentrated in vacuo to give 549 g(93%) of colorless N² -butyl valeric acid hydrazide: mp 66.0°-67.5° C.;NMR (CDCl₃) δ0.92 (t, J=7Hz, 6H), 1.17-1.52 (m, 6H), 1.56-1.69 (m, 2H),2.14 (t, J=7Hz, 2H), 2.82 (t, J=7Hz, 2H).

Step 3; Preparation of 2-bromo-5-picoline

A solution of 1500 mL (14 mol) of 48% hydrobromic acid was cooled to 10°C. and 300 g (2.8 mol) of 2-amino-5-picoline (Aldrich) was added slowly.The solution was maintained at or below 0° C. while 450 mL (8.8 mol) ofbromine was added dropwise. After the bromine addition was complete, asolution of 500 g (7.3 mol) of sodium nitrite in 1000 mL of water wasadded slowly over 6 h. The reaction pH was adjusted by the carefuladdition of 1500 mL (56 mol) of 50% sodium hydroxide at such a rate thatthe temperature was maintained below 30° C. The product precipitatedfrom the nearly colorless reaction mixture; filtration gave 450 g (94%)of 2-bromo-5-picoline as a yellow powder: mp 38°-40° C.; NMR 7.27 (s,1H), 7.28 (s, 1H), 7.12 (br s, 1H).

Step 4; Preparation of 2-bromo-5-romomethylpyridine

A solution of 296.3 g (1.72 mol) of 2-bromo-5picoline from step 3 in 6 Lof carbon tetrachloride was treated with 306.5 g (1.72 tool) ofN-bromosuccinimide (NBS) and 28.3 g 173 mmol) of azobisisobutyronitrile(AIBN). The reaction was stirred at reflux under nitrogen for 3 h,filtered, and concentrated in vacuo providing 476 g of crude2-bromo-5-bromomethylpyridine as a brownish yellow solid (NMR indicatesthat this material is only 60% monobromomethyl product): NMR (CDCl₃) 64.42 (s, 2H), 7.48 (d, J=9Hz, 1H), 7.60 (dd, 2=9 and 3Hz, 1H), 8.37 (d,J=3Hz, 1H).

Step 5: Preparation of 2-bromo-5-cyanomethyl-pyridine.

The 476 g of crude 2-bromo-5-bromomethylpyridine from step 4 wasdissolved in 4000 mL of dimethylformamide (DMF)/water (7:1) and treatedwith 168 g (2.58 mol) of potassium cyanide. The reaction was allowed tostir at ambient temperature for 72 h, concentrated in vacuo, andpartitioned between ethyl acetate and water; the organic layer waswashed with water, washed with brine, dried (MgSO₄), and reconcentratedin vacuo to provide the crude nitrile. Purification by silica gelchromatography (Waters Prep-500A) using ethyl acetate/hexane (25:75)gave 109 g (32% from 2-bromo-5-picoline) of2-bromo-5-cyanomethylpyridine as a yellowish orange solid: mp55.5°-57.5° C; NMR (CDCl₃) δ 3.74 (s, 2H), 7.54 (d, J=8Hz, 1H), 7.59(dd, J=8 and 2 HZ, 1H), 8.35 (d, J=2Hz, 1H); MS (FAB) m/e (relintensity) 199 (85), 197 (100).

Step 6: Preparation of ethyl imino(2-bromopyridin-5-yl)acetate

Under nitrogen, 299 mL (4.20 mol) of acetyl chloride was added dropwiseto a solution of 299 mL (5.11 tool) of absolute ethanol and 400 mL ofchloroform at 0° C. A solution of 72.0 g (370 mmol) of2-bromo-5cyanomethylpyridine from step 5 in 1100 mL of chloroform wasadded dropwise with stirring. Stirring was continued at 0° C. for 4 hand the reaction was allowed to come to ambient temperature overnight.The reaction was diluted with 2500 mL of anhydrous ether and stirringwas continued for an additional 2 h. The precipitated imidatehydrochloride salt was collected by filtration in a glove bag undernitrogen and washed with anhydrous ether. Under nitrogen, a mechanicallystirred suspension of this material in 3500 mL of anhydrous ether at-78° C. was treated with 36 g (2.1 mol) of anhydrous ammonia. Thereaction was allowed to slowly warm to ambient temperature overnight andthe ammonium chloride removed by filtration. The filtrate wasconcentrated in vacuo giving 8.7 g (89%) of crude ethylimino(2-bromopyridin-5-yl) acetate as a brown oil: NMR (CDCl₃) δ 1.29(t, J=7Hz, H), 3.51 (s, 2H), 4.13 (q, J=7Hz, 2H), 7.43 (dd, J=8 and Hz,1H), 7.48 (d, J=8Hz, 1H), 8.26 (d, J=2Hz, 1H); MS (FAB) m/e (relintensity) 245 (100), 243 (90), 217 (35), 215 (38), 200 (5), 198 (5).

Step 7: preparation of 2-bromo-5-[(1,3-dibutyl-1H-1,2,4 -triazol-5-yl)methyl]pyridine

Under nitrogen, a solution of 1.2 g (5 mmol) of imidate ester from step6 and 850 mg (5 mmol) of N² -butyl valeric acid hydrazide from step 2 in25 mL of absolute methanol was stirred for 24 h at ambient temperature.The methanol was removed in vacuo and replaced with 25 mL of anhydroustoluene. The reaction vessel was equipped with a Dean-Stark trap and thereaction stirred at reflux for 48 h. Concentration in vacuo produced thecrude product residue. Purification by silica gel chromatography (WatersPrep-500A) using ethyl acetate/hexane (60:40) gave 700 mg (40%) of2-bromo-5-[(1, 3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]pyridine as anoil: NMR (CDCl₃) δ 0.88 (t, J=7Hz, 3H), 0.92 (t, J=7Hz, 3H), 1.25-1.75(m, 8H), 2.67 (t, J=8Hz, 2H), 3.93 (t, J= 7Hz, 2H), 4.05 (s, 2H), 7.43(s, 1H), 7.44 (s, 1H), 8.27 (s, 1H); MS (FAB)m/e (rel intensity) 353(50), 351 (50), 297 (100), 295 (100), 215 (40), 160 (90), 158 (90), 138(70).

Step 8: Preparation of 5-[2-[5-[(1,3-dibutyl-1H-1,2,4 -triazol-5-yl)methyl]-2-pyridinyl]phenyl-1H-tetrazole

Under nitrogen, a solution of 700 mg (2.0 mmol) of2-bromo-5-[(1,3-dibutyl-1H-1,2,4-triazol-5yl)methyl]pyridine from seep 7and 180 mg (0.16 mmol) of tetrahis (tri-phenylphosphine)palladium in 12mL of toluene and 3 mL of 2M sodium carbonate was treated with asolution of 1.12 g (2.6 mmol) of2-(N-triphenylmethyltetrazol-5-yl)phenylboronic acid from step 1 in 3 mLof ethanol. The reaction was vigorously stirred at reflux for 17 h. Thereaction was cooled to ambient temperature and three immiscible phaseseparated; the middle phase contained the deprotected tetrazole product.Purification by reverse phase chromatography (Waters Deltaprep-3000)using isocratic acetonitrile/water (27: 73) (0.05% TFA) gave 300 mg(28%) of colorless 5-[2-[5-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl )methyl]-2-pyridinyl]phenyl-1H-tetrazole as the trifluoroacetic acid(TFA) salt after lyophilization: NMR (CDCl₃) δ 0.93 (t, J=7Hz, 6H),1.26-1.46 (m, 4H), 1.67-1.89 (m, 4H), 2.74 (t, J=8Hz, 2H), 4.10 (t,J=7Hz, 2H), 4.30 (s, 2H), 7.43 (d, J=8Hz, 1H), 7.53-7.62 (m, 3H), 7.74(dd, J=8 and 2 Hz, 1H), 8.02-8.05 (m, 1H), 8.52 (d, J=2Hz, 1H); MS (FAB)m/e (rel intensity) 417 (100), 389 (75), 361 (20); HRMS. Calc'd for M+H:417.2515. Found: 417.2516.

BIOLOGICAL EVALUATION Assay A: Angiotensin II Binding Activity

Compounds of the invention were tested for ability to bind to the smoothmuscle angiotensin II receptor using a rat uterine membrane preparation.Angiotensin II (AII) was purchased from Peninsula Labs. ¹²⁵I-angiotensin II (specific activity of 2200 Ci/mmol) was purchased fromDu Pont-New England Nuclear. Other chemicals were obtained from SigmaChemical Co. This assay was carried out according to the method ofDouglas et al [Endocrinology, 106, 120-124 (1980)]. Rat uterinemembranes were prepared from fresh tissue. All procedures were carriedout at 4° C. Uteri were stripped of fat and homogenized inphosphate-buffered saline at pH 7.4 containing 5 mM EDTA. The homogenatewas centrifuged at 1500 × g for 20 min., and the supernatant wasrecentrifuged at 100,000 × g for 60 min. The pellet was resuspended inbuffer consisting of 2 mM EDTA and 50 mM Tris-HC1 (pH 7.5) to a finalprotein concentration of 4 mg/ml. Assay tubes were charged with 0.25 mlof a solution containing 5 mM MgCl₂, 2 mM EDTA, 0.5% bovine serumalbumin, 50 mM Tris-HCl, pH 7.5 and ¹²⁵ I-AII (approximately 10⁵ cpm) inthe absence or in the presence of unlabelled ligand. The reaction wasinitiated by the addition of membrane protein and the mixture wasincubated at 25° C. for 60 min. The incubation was terminated withice-cold 50 mM Tris-HCl (pH 7.5) and the mixture was filtered toseparate membrane-bound labelled peptide from the free ligand. Theincubation tube and filter were washed with ice-cold buffer. Filterswere assayed for radioactivity in a Micromedic gamma counter.Nonspecific binding was defined as binding in the presence of 10 μM ofunlabelled AII. Specific binding was calculated as total binding minusnonspecific binding. The receptor binding affinity of an AII antagonistcompound was indicated by the concentration (IC₅₀) of the tested AIIantagonist which gives 50% displacement of the total specifically bound¹²⁵ I-AII from the high affinity AII receptor. Binding data wereanalyzed by a nonlinear least-squares curve fitting program. Results arereported in Table I.

Assay B: In Vitro Vascular Smooth Muscle-Response for AII

The compounds of the invention were tested for antagonist activity inrabbit aortic rings. Male New Zealand white rabbits (2-2.5 kg) weresacrificed using an overdose of pentobarbital and exsanguinated via thecarotid arteries. The thoracic aorta was removed, cleaned of adherentfat and connective tissue and then cut into 3-mm ring segments. Theendothelium was removed from the rings by gently sliding a rolled-uppiece of filter paper into the vessel lumen. The rings were then mountedin a water-jacketed tissue bath, maintained at 37° C. between moveableand fixed ends of a stainless steel wire with the moveable end attachedto an FT03 Grass transducer coupled to a Model 7D Grass Polygraph forrecording isometric force responses. The bath was filled with 20 ml ofoxygenated (95% oxygen/5% carbon dioxide) Krebs solution of thefollowing composition (mM): 130 NaCl, 15 NaHCO₃, 15 KCl, 1.2 NaH₂ PO₄,1.2 MgSO₄, 2.5 CaCl₂, and 11.4 glucose. The preparations wereequilibrated for one hour before approximately one gram of passivetension was placed on the rings. Angiotensin II concentration-responsecurves were then recorded (3×10⁻¹⁰ to 1×10⁻⁵ M). Each concentration ofAII was allowed to elicit its maximal contraction, and then AII waswashed out repeatedly for 30 minutes before rechallenging with a higherconcentration of AII. Aorta rings were exposed to the test antagonist at10⁻⁵ M for 5 minutes before challenging with AII. Adjacent segments ofthe same aorta ring were used for all concentration-response curves inthe presence or absence of the test antagonist. The effectiveness of thetest compound was expressed in terms of pA₂ values and were calculatedaccording to H. O. Schild [Br. J. Pharmacol. Chemother., 2,189-206(1947)]. The pA₂ value is the concentration of the antagonist whichincreases the EC50 value for AII by a factor of two. Each testantagonist was evaluated in aorta rings from two rabbits. Results arereported in Table I.

                  TABLE I                                                         ______________________________________                                        In Vitro Angiotensin II                                                       Activity of Compounds of the Invention                                                         .sup.1 Assay A                                               Test Compound    IC.sub.50                                                                              .sup.2 Assay B                                      Example #        (nM)     pA.sub.2                                            ______________________________________                                        1                31       7.80/7.91                                           ______________________________________                                         .sup.1 Assay A: Angiotensin II Binding Activity                               .sup.2 Assay B: In Vitro Vascular Smooth Muscle Response                 

Also embraced within this invention is a class of pharmaceuticalcompositions comprising one or more compounds of Formula I inassociation with one or more nontoxic, pharmaceutically acceptablecarriers and/or diluents and/or adjuvants (collectively referred toherein as "carrier" materials) and, if desired, other activeingredients. The compounds of the present invention may be administeredby any suitable route, preferably in the form of a pharmaceuticalcomposition adapted to such a route, and in a dose effective for thetreatment intended. Therapeutically effective doses of the compounds ofthe present invention required to prevent or arrest the progress of themedical condition are readily ascertained by one of ordinary skill inthe art. The compounds and composition may, for example, be administeredintravascularly, intraperitoneally, subcutaneously, intramuscularly ortopically.

For oral administration, the pharmaceutical composition may be in theform of, for example, a tablet, capsule, suspension or liquid. Thepharmaceutical composition is preferably made in the form of a dosageunit containing a particular amount of the active ingredient. Examplesof such dosage units are tablets or capsules. These may with advantagecontain an amount of active ingredient from about 1 to 250 mg,preferably from about 25 to 150 mg. A suitable daily dose for a mammalmay vary widely depending on the condition of the patient and otherfactors. However, a dose of from about 0.1 to 3000 mg/kg body weight,particularly from about 1 to 100 mg/kg body weight, may be appropriate.

The active ingredient may also be administered by injection as acomposition wherein, for example, saline, dextrose or water may be usedas a suitable carrier. A suitable daily dose is from about 0.1 to 100mg/kg body weight injected per day in multiple doses depending on thedisease being treated. A preferred daily dose would be from about 1 to30 mg/kg body weight. Compounds indicated for prophylactic therapy willpreferably be administered in a daily dose generally in a range fromabout 0.1 mg to about 100 mg per kilogram of body weight per day. A morepreferred dosage will be a range from about 1 mg to about 100 mg perkilogram of body weight. Most preferred is a dosage in a range fromabout 1 to about 50 mg per kilogram of body weight per day. A suitabledose can be administered, in multiple sub-doses per day. These subdosesmay be administered in unit dosage forms. Typically, a dose or sub-dosemay contain from about 1 mg to about 100 mg of active compound per unitdosage form. A more preferred dosage will contain from about 2 mg toabout 50 mg of active compound per unit dosage form. Most preferred is adosage form containing from about 3 mg to about 25 mg of active compoundper unit dose.

The dosage regimen for treating a disease condition with the compoundsand/or compositions of this invention is selected in accordance with avariety of factors, including the type, age, weight, sex and medicalcondition of the patient, the severity of the disease, the route ofadministration, and the particular compound employed, and thus may varywidely.

For therapeutic purposes, the compounds of this invention are ordinarilycombined with one or more adjuvants appropriate to the indicated routeof administration. If administered per os, the compounds may be admixedwith lactose, sucrose, starch powder, cellulose esters of alkanoicacids, cellulose alkyl esters, talc, stearic acid, magnesium stearate,magnesium oxide, sodium and calcium salts of phosphoric and sulfuricacids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone,and/or polyvinyl alcohol, and then tableted or encapsulated forconvenient administration. Such capsules or tablets may contain acontrolled-release formulation as may be provided in a dispersion ofactive compound in hydroxypropylmethy cellulose. Formulations forparenteral administration may be in the form of aqueous or non-aqueousisotonic sterile injection solutions or suspensions. These solutions andsuspensions may be prepared from sterile powders or granules having oneor more of the carriers or diluents mentioned for use in theformulations for oral administration. The compounds may be dissolved inwater, polyethylene glycol, propylene glycol, ethanol, corn oil,cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride,and/or various buffers. Other adjuvants and modes of administration arewell and widely known in the pharmaceutical art.

Although this invention has been described with respect to specificembodiments, the details of these embodiments are not to be construed aslimitations.

What is claimed is:
 1. A therapeutic method for treating a circulatorydisorder, said method comprising administering to a subject susceptibleto or afflicted with such disorder a therapeutically-effective amount ofa compound of Formula I ##STR64## wherein A is selected from ##STR65##wherein m is a number selected from one to four, inclusive; wherein R¹is selected from hydrido, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl,cycloalkylalkyl, formyl, aralkyl, aryl, aroyt, alkoxyalkyl,alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkenyl,cycloalkenyl, aralkoxycarbonyl, alkynyl, alkylthiocarbonyl,alkylthiothiocarbonyl, arylthiocarbonyl, arylthiothiocarbonyl,aralkylthiocarbonyl, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl,aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroarylhaving one or more-ring atoms selected from oxygen, sulfur and nitrogenatoms, and amido radicals of the formula ##STR66## wherein X is oxygenatom or sulfur atom; wherein each of R¹² and R¹³ is independentlyselected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino,dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl andaryl or tetrazole;wherein each of R² through R¹¹ is independentlyselected from hydrido, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl,cycloalkylalkyl, cycloalkylhaloalkyl, cycloalkylcarbonyl, formyl,alkoxy, aralkyl, aralkylhaloalkyl, aryl, aroyl, aryloxy, aryloxyalkyl,aralkoxy, alkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl,alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl,carboxyalkyl, alkynyl, cyano, nitro, carboxyl, carboxyalkyl,alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl,mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio,cycloalkylthio, cycloalkylalkylthio, alkylthiocarbonyl,alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio,alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio,arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy,arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio,aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio,aralkylthiocarbonyloxy, aralkylthiocarbonylthio, alkylthiocarbonyl,aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl,aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl,phthalimido, phthalimidoalkyl, and wherein each of R² through R¹¹ may befurther independently selected from amino and amido radicals of theformula ##STR67## wherein X is oxygen atom or sulfur atom; wherein eachn is a number independently selected from zero to six, inclusive;wherein each of R¹⁴ through R²⁶ is independently selected from hydrido,alkyl, cycloalkyl, cyano, amino, monoalkylamino, dialkylamino,hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, andwherein each of R³ through R¹¹ may be further independently selectedfrom hydroxy and acidic moieties of the formula

    --Y.sub.n A

wherein n is a number selected from zero through three, inclusive, andwherein A is an acidic group selected to contain at least one acidichydrogen atom, and the amide, ester and salt derivatives of said acidicmoieties; wherein Y is a spacer group independently selected from one ormore of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl,aralkyl and heteroaryl having one or more ring atoms selected fromoxygen, sulfur and nitrogen atoms; and wherein any of the foregoing R¹through R²⁶, Y and A groups having a substitutable position may besubstituted by one or more groups independently selected from hydroxy,alkyl, alkenyl, alkynyl, aralkyl, hydroxyalkyl, haloalkyl, halo, oxo,alkoxy, aryloxy, aralkoxy, aralkylthio, alkoxyalkyl, cycloalkyl,cycloalkylalkyl, aryl, aroyl, cycloalkenyl, cyano, cyanoamino, nitro,alkylcarbonyloxy, alkoxycarbonyloxy, alkylcarbonyl, alkoxycarbonyl,aralkoxycarbonyl, carboxyl, mercapto, mercaptocarbonyl, alkylthio,arylthio, alkylthiocarbonyl, alkylsulfinyl, alkylsulfonyl,haloalkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl,arylsulfonyl, amino and amido radicals of the formula ##STR68## whereinX is oxygen atom or sulfur atom; wherein each of R²⁷ through R^(3i) isindependently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl,aralkyl, aryl, DR³² and ##STR69## wherein D is selected from oxygen atomand sulfur atom and R³² is selected from hydrido, alkyl, cycloalkyl,cycloalkylalkyl, aralkyl and aryl; wherein each of R²⁷, R²⁸, R²⁹, R³⁰,R³¹, R³³ and R³⁴ is independently selected from hydrido, alkyl,cycloalkyl, cyano, hydroxyalkyl, haloalkyl, cycloalkylalkyl,alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, alkylsulfinyl,alkylsulfonyl, arylsulfinyl, arylsulfonyl, haloalkylsulfinyl,haloalkylsulfonyl, aralkyl and aryl, and wherein each of R²⁷, R²⁸, R²⁹,R³⁰, R³¹, R³³ and R³⁴ is further independently selected from amino andamido radicals of the formula ##STR70## wherein X is oxygen atom orsulfur atom; wherein each of R³⁵, R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰ isindependently selected from hydrido, alkyl, cycloalkyl, cyano,hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, haloalkylsulfinyl,haloalkylsulfonyl, aralkyl and aryl.
 2. The method of claim 1 wherein mis one; wherein R¹ is selected from hydrido, alkyl, hydroxyalkyl,haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, aroyl,alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl,alkynyl, cycloalkynyl, carboxyl, alkylthiocarbonyl, arylthiocarbonyl,arylthiothiocarbonyl, aralkylthiocarbonyl, alkylsulfonyl,aralkylsulfonyl, arylsulfonyl, and amido radicals of the formula##STR71## wherein X is oxygen atom or sulfur atom; wherein each of R¹²and R¹³ is independently selected from hydrido, alkyl, cycloalkyl,cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl,cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl;wherein R² is selectedfrom hydrido, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl,cycloalkylalkyl, cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy,aralkyl, aralkylhaloalkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy,alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl,alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl,alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl,mercaptothiocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio,cycloalkylthio, cycloalkylalkylthio, alkylthiocarbonyl,alkylcarbonylthio, alkylthiocarbonyloxy, alkylthiocarbonylthio,alkylthiothiocarbonyl, alkylthiothiocarbonylthio, arylthio,arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy,arylthiocarbonylthio, arylthiothiocarbonyl, arylthiothiocarbonylthio,aralkylthio, aralkylthiocarbonyl, aralkylcarbonylthio,aralkylthiocarbonyloxy, aralkylthiocarbonylthio, aralkylthiocarbonyl,aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl,aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl,phthalimido, phthalimidoalkyl, and nitrogen atoms, and wherein each ofR² through R¹¹ may be further independently selected from amino andamido radicals of the formula ##STR72## wherein X is selected fromoxygen atom or sulfur atom; wherein each n is a number independentlyselected from zero to six, inclusive; wherein each of R¹⁴ through R²⁶ isindependently selected from hydrido, alkyl, cycloalkyl, cyano, amino,monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl,alkoxyalkyl, aralkyl and aryl; wherein each of R³ through R¹¹ isindependently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aralkyl, aryl, aroyl,aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl,cycloalkenyl, alkynyl, cycloalkynyl, cyano, nitro, carboxyl,alkylcarbonyloxy, mercaptocarbonyl, mercaptothiocarbonyl,alkoxycarbonyloxy, alkylthio, alkylthiocarbonyl, alkylcarbonylthio,alkylthiocarbonyloxy, alkylthiocarbonylthio, alkylthiothiocarbonyl,arylthio, arylthiocarbonyl, arylcarbonylthio, arylthiocarbonyloxy,arylthiothiocarbonyl, aralkylthio, aralkylthiocarbonyl,aralkylcarbonylthio, aralkylthiocarbonyloxy, aralkylthiocarbonylthio,aralkylthiocarbonyl, aralkylthiocarbonylthio, mercapto, alkylsulfonyl,aralkylsulfonyl and arylsulfonyl, and amino and amido radicals of theformula ##STR73## wherein X is oxygen atom or sulfur atom; wherein eachof R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ is independently selected fromhydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, cycloalkylalkyl,alkoxyalkyl, aralkyl and aryl; and wherein each of R³ through R¹¹ may befurther independently selected from acidic moieties of the formula

    --Y.sub.n A

wherein n is a number selected from zero through three, inclusive;wherein A is an acidic group selected from acids containing one or moreatoms selected from oxygen, sulfur, phosphorus and nitrogen atoms, andwherein said acidic group is selected to contain at least one acidichydrogen atom, and the amide, ester and salt derivatives of said acidicmoieties; wherein Y is a spacer group independently selected from one ormore of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, aryl,aralkyl and tetrazole; and wherein any of the foregoing R¹ through R²⁶,Y and A groups having a substitutable position may be substituted by oneor more groups independently selected from hydroxy, alkyl, alkenyl,aralkyl, hydroxyalkyl, halo, haloalkyl, oxo, alkoxy, aryloxy, aralkoxy,alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro,alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, mercaptocarbonyl,alkylthio and alkylthiocarbonyl, and amino and amido radicals of theformula ##STR74## wherein X is oxygen atom or sulfur atom; wherein eachof R²⁷ through R³¹ is independently selected from hydrido, alkyl,cycloalkyl, cycloalkylalkyl, aralkyl, aryl, and DR³² and ##STR75##wherein D is selected from oxygen atom and sulfur atom, and R³² isselected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl andaryl; wherein each of R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³³ and R³⁴ isindependently selected from hydrido, alkyl, cycloalkyl, cyano,hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, alkanoyl,alkoxycarbonyl, carboxyl, haloalkylsulfinyl, haloalkylsulfonyl, aralkyland aryl; or a tautomer thereof or a pharmaceutically-acceptable saltthereof.
 3. The method of claim 2 wherein m is one;wherein R¹ isselected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl,cycloalkylalkyl, aralkyl, aryl, aroyl, alkoxyalkyl, alkylcarbonyl,alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, carboxyl,alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and amido radicals ofthe formula ##STR76## wherein each of R¹² and R¹³ is independentlyselected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino,dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl andaryl; wherein R² is selected from hydrido, alkyl, hydroxyalkyl, halo,haloalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylhaloalkyl,cycloalkylcarbonyl, alkoxy, aralkyl, aralkylhaloalkyl, aryl, aroyl,aryloxy, aryloxyalkyl, aralkoxy, alkoxyalkyl, alkylcarbonyl,alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, cyano,nitro, carboxyl, carboxyalkyl, alkylcarbonyloxy, mercaptocarbonyl,alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, alkylthio,cycloalkylthio, cycloalkylalkylthio, arylthio, aralkylthio,aralkylthiocarbonylthio, mercapto, alkylsulfinyl, alkylsulfonyl,aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl,phthalimido, phthalimidoalkyl, and wherein R² may be further selectedfrom amino and amido radicals of the formula ##STR77## wherein X isselected from oxygen atom or sulfur atom; wherein each n is a numberindependently selected from zero to six, inclusive; wherein each of R¹⁴through R²⁶ is independently selected from hydride, alkyl, cycloalkyl,cyano, amine, monoalkylamino, dialkylamino, hydroxyalkyl,cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; wherein each of R³through R¹¹ is independently selected from hydride, hydroxy, alkyl,hydroxyalkyl, halo, haloalkyl, cycloalkyl, alkoxy, aralkyl, aryl, aroyl,aryloxy, aralkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl,cycloalkenyl, alkynyl, cyano, nitre, carboxyl, alkylcarbonyloxy,mercaptocarbonyl, alkoxycarbonyloxy, alkylthio, arylthio, aralkylthio,mercapto, alkylsulfonyl, aralkylsulfonyl and arylsulfonyl, and amine andamido radicals of the formula ##STR78## wherein each of R¹⁴, R¹⁵, R¹⁶,R¹⁷, R¹⁸ and R¹⁹ is independently selected from hydride, alkyl,cycloalkyl, cyano, amino, monoalkylamino, dialkylamino, hydroxyalkyl,cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl; and wherein each of R³through R¹¹ may be further independently selected from acidic moietiesof the formula

    --Y.sub.n A

wherein n is a number selected from zero through three, inclusive;wherein the A group is selected to have an acidic proton, such that whenthe --Y_(n) A moiety is incorporated within a compound of Formula I,there is provided a compound of Formula I having a pK_(a) in a rangefrom about two to about seven, said A group selected from carboxylicacid and bioisosteres of carboxylic acid selected from ##STR79## whereineach W is independently selected from oxygen atom, sulfur atom and NR³⁹; wherein each of R³⁵, R³⁶, R³⁷, R³⁸ and R³⁹ is independently selectedfrom hydrido, alkyl, haloalkyl, haloalkylsulfonyl, haloalkylcarbonyl,cycloalkyl, cycloalkylalkyl, aryl and aralkyl; wherein each of R³⁵, R³⁶,R³⁷ and R³⁹ may be further independently selected from amino radical ofthe formula ##STR80## wherein each of R⁴⁰ and R⁴¹ is independentlyselected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl,cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl, and wherein Y is aspacer group independently selected from one or more of alkyl,cycloalkyl, cycloalkylalkyl, alkenyl, aryl and aralkyl; and wherein anyof the foregoing R¹ through R²⁶ and R³⁵ through R⁴¹, Y and A groupshaving a substitutable position may be substituted by one or more groupsindependently selected from hydroxy, alkyl, alkenyl, aralkyl,hydroxyalkyl, halo, oxo, haloalkyl, alkoxy, aryloxy, aralkoxy,alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, carboxyl, cyano, nitro,alkylsulfonyl, haloalkylsulfonyl, aryl, aralkyl, mercaptocarbonyl,alkylthio and alkylthiocarbonyl, and amino and amido radicals of theformula ##STR81## wherein X is selected from oxygen atom and sulfuratom; wherein R²⁷ is selected from hydrido, alkyl, cycloalkyl,cycloalkylalkyl, aralkyl, aryl and DR³² and ##STR82## wherein D isselected from oxygen atom and sulfur atom; wherein R³² is selected fromhydrido, alkyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl; whereineach of R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³³ and R³⁴ is independently selectedfrom hydrido, alkyl, cycloalkyl, cyano, hydroxyalkyl, haloalkyl,cycloalkylalkyl, alkoxyalkyl, alkanoyl, alkoxycarbonyl, carboxyl,haloalkylsulfinyl, haloalkylsulfonyl, aralkyl and aryl; or a tautomerthereof or a pharmaceutically-acceptable salt thereof.
 4. The method ofclaim 3 wherein m is one; wherein R¹ is selected from hydrido, alkyl,hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl,aroyl, alkoxyalkyl, alkylcarbonyl, alkenyl, cycloalkenyl, alkynyl,mercaptocarbonyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl and amidoradicals of the formula ##STR83## wherein each of R¹² and R¹³ isindependently selected from hydrido, alkyl, cycloalkyl, cyano, amino,monoalkylamino, dialkylamino, hydroxyalkyl, cycloalkylalkyl,alkoxyalkyl, aralkyl and aryl tetrazole;wherein R² is selected fromhydrido, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl,cycloalkylalkyl, cycloalkylhaloalkyl, cycloatkylcarbonyl, alkoxy,aralkyl, aralkylhaloalkyl, aryl, aroyl, aryloxy, aryloxyalkyl, aralkoxy,alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl,alkynyl, cycloalkynyl, cyano, nitro, carboxyl, carboxyalkyl,alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, mercaptocarbonyl,mercaptoalkyl, alkoxycarbonyioxy, alkylthio, cycloalkylthio,cycloalkylalkylthio, arylthio, aralkylthio, mercapto, alkylsulfinyl,alkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl,arylsulfonyl, phthalimido, phthalimidoalkyl, and wherein each of R²through R¹¹ may be further independently selected from amino and amidoradicals of the formula ##STR84## wherein X is selected from oxygen atomand sulfur atom; wherein each n is a number independently selected fromzero to six, inclusive; wherein each of R¹⁴ through R²⁶ is independentlyselected from hydrido, alkyl, cycloalkyl, cyano, amino, monoalkylamino,dialkylamino, hydroxyalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl andaryl; wherein each of R³ through R¹¹ is independently selected fromhydrido, hydroxy, alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl,alkoxy, aralkyl, aryl, aroyl, aryloxy, aralkoxy, alkoxyalkyl,alkylcarbonyl, alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano,nitro, carboxyl, alkylthio, aralkylthio and mercapto; and wherein eachof R³ through R¹¹ may be further independently selected from acidicmoieties of the formula

    --Y.sub.n A

wherein n is a number selected from zero through three, inclusive;wherein A is selected from carboxylic acid and bioisosteres ofcarboxylic acid selected from ##STR85## wherein each W is independentlyselected from oxygen atom, sulfur atom and NR³⁹ ; wherein each of R³⁵,R³⁸ and R³⁹ is independently selected from hydrido, alkyl, haloalkyl,haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, cycloalkylalkyl, aryland aralkyl; wherein each of R³⁵ and R³⁹ may be further independentlyselected from amino radical of the formula ##STR86## wherein each of R⁴⁰and R⁴¹ is independently selected from hydrido, alkyl, cycloalkyl,hydroxyalkyl, haloalkyl, cycloalkylalkyl, alkoxyalkyl, aralkyl and aryl,and wherein Y is a spacer group independently selected from one oraralkyl; wherein each of R¹ through R²⁶, R³⁵ and R³⁸ through R⁴¹, Y andA independently may be substituted at any substitutable position withone or more groups selected from alkyl, hydroxy, halo, oxo, haloalkyl,alkoxycarbonyl, cyano, nitro, alkylsulfonyl, haloalkylsulfonyl, aryl,aralkyl, alkoxy, aryloxy and aralkoxy; or a tautomer thereof or apharmaceutically-acceptable salt thereof.
 5. The method of claim 4wherein m is one; wherein R¹ is selected from hydrido, alkyl,hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl,aroyl, alkoxyalkyl, alkylcarbonyl, alkenyl, alkynyl, alkylsulfonyl,aralkylsulfonyl, arylsulfonyl and amido radicals of the formula##STR87## wherein each of R¹² and R¹³ is independently selected fromhydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl, alkoxyalkyl,phenalkyl and phenyl;wherein R² is selected from hydrido, alkyl,hydroxyalkyl, halo, haloalkyl, cycloalkyl, cycloalkylalkyl,cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy, aralkyl,aralkylhaloalkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy,phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, alkylcarbonyl,alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl,carboxyalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl,alkoxycarbonylalkyl, aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl,mercaptocarbonyl, mercaptoalkyl, alkoxycarbonyloxy, alkylthio,cycloalkylthio, cycloalkylalkylthio, phthalimido, phthalimidoalkyl, andwherein each of R² through R¹¹ may be further independently selectedfrom amino and amido radicals of the formula ##STR88## wherein X isselected from oxygen atom and sulfur atom; wherein each n is a numberindependently selected from zero to six, inclusive; wherein each of R¹⁴through R²⁶ is independently selected from hydrido, alkyl, cycloalkyl,cyano, amino, hydroxyalkyl, alkoxyalkyl, phenalkyl and phenyl; whereineach of R³ through R¹¹ is independently selected from hydrido, hydroxy,alkyl, hydroxyalkyl, halo, haloalkyl, cycloalkyl, alkoxy, phenalkyl,phenyl, benzoyl, phenoxy, phenalkyloxy, alkoxyalkyl, alkylcarbonyl,alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto;and wherein each of R³ through R¹¹ may be further independently selectedfrom acidic moieties of the formula

    --Y.sub.n A

wherein n is a number selected from zero through two, inclusive; whereinA is selected from carboxylic acid and bioisosteres of carboxylic acidselected from ##STR89## wherein each W is independently selected fromoxygen atom, sulfur atom and NR³⁹ ; wherein each of R³⁵, R³⁸ and R³⁹ isindependently selected from hydrido, alkyl, haloalkyl,haloalkylsulfonyl, haloalkylcarbonyl, cycloalkyl, phenyl and benzyl;wherein each of R³⁵ and R³⁹ may be further independently selected fromamino radical of the formula ##STR90## wherein each of R⁴⁰ and R⁴¹ isindependently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl,haloalkyl, alkoxyalkyl, benzyl and phenyl; and the amide, ester and saltderivatives of said acidic groups; wherein Y is a spacer groupindependently selected from one or more of alkyl, cycloalkyl,cycloalkylalkyl, alkenyl, phenyl, phenalkyl and aralkyl; wherein each ofR¹ through R²⁶, R³⁵ and R³⁸ through R⁴¹, Y and A and independently maybe substituted at any substitutable position with one or more groupsselected from alkyl, cycloalkyl, cycloalkylalkyl, hydroxy, halo, oxo,haloalkyl, alkoxycarbonyl, cyano, nitro, alkylsulfonyl,haloalkylsulfonyl, aryl, aralkyl, alkoxy, aryloxy and aralkoxy; or atautomer thereof or a pharmaceutically-acceptable salt thereof.
 6. Themethod of claim 5 wherein m is one; wherein R¹ is selected from hydrido,alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl,aryl, benzoyl, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkenyl andalkynyl; where R² is selected from alkyl, aminoalkyl, hydroxyalkyl,halo, haloalkyl, cycloalkyl, cycloalkylalkyl, alkylcarbonyl,cycloalkylhaloalkyl, cycloalkylcarbonyl, alkoxy, aralkyl,aralkylhaloalkyl, aryl, benzoyl, phenoxy, phenoxyalkyl, phenalkyloxy,phenylthio, phenalkylthio, aralkoxy, alkoxyalkyl, acetyl,alkoxycarbonyl, alkenyl, cycloalkenyl, alkynyl, cyano, nitro, carboxyl,carboxyalkyl, alkylcarbonyloxy, mercaptoalkyl, mercaptocarbonyl,alkoxycarbonyloxy, alkylcarbonyloxyalkyl, alkoxycarbonylalkyl,aralkoxycarbonylalkyl, aralkylcarbonyloxyalkyl, phthalimido,phthalimidoalkyl, imidazoalkyl, tetrazole, tetrazolealkyl, alkylthio,cycloalkylthio, cycloalkylalkylthio, and amino and amido radicals of theformula ##STR91## wherein X is selected from oxygen atom and sulfuratom; wherein each n is a number independently selected from zero tosix, inclusive;wherein each of R¹⁴ through R²⁶ is independently selectedfrom hydrido, alkyl, cycloalkyl, cyano, amino, hydroxyalkyl,alkoxyalkyl, phenalkyl and phenyl; wherein each of R³ through R¹¹ isindependently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, halo,haloalkyl, alkoxy, phenyl, benzoyl, phenoxy, alkoxyalkyl, acetyl,alkoxycarbonyl, alkenyl, cyano, nitro, carboxyl, alkylthio and mercapto;and wherein each of R³ through R¹¹ may be further independently selectedfrom acidic moieties consisting of CO₂ H, CO₂ CH₃, SH, CH₂ SH, C₂ H₄ SH,PO₃ H₂, NHSO₂ CF₃, NHSO₂ C₆ F₅, SO₃ H, CONHNH₂, CONHNHSO₂ CF₃, CONHOCH₃,CONHOC₂ H₅, CONHCF₃, OH, CH₂ OH, C₂ H₄ OH, OPO₃ H₂, OSO₃ H, tetrazoleand the esters, amides and salts of said acidic moieties; or a tautomerthereof or a pharmaceutically-acceptable salt thereof.
 7. The method ofclaim 6 wherein m is one; wherein R¹ is selected from methyl, ethyl,n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl,isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl,cyclohexylmethyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and2-hydroxybutyl; wherein R² is selected from C₄ H₉ (n), CH₃ CH₂ CH═CH, C₃H₇ (n), SC₃ H₇, ##STR92## amino, aminomethyl, aminoethyl, aminopropyl,acetyl, CH₂ OH CH₂ OCOCH₃, CH₂ Cl, Cl, CH₂ OCH₃, CH₂ OCH(CH₃)₂ I, CHO,##STR93## --CH₂ NHCO₂ CH₂ (CH₃)₂, --CH₂ NHCO₂ C₄ H₉, CH₂ NHCO₂-adamantyl, --CH₂ NHCO₂ --(1-napthyl), --CH₂ NHCONHCH₃, --CH₂ NHCONHC₂H₅, --CH₂ NHCONHC₃ H₇, --CH₂ NHCONHC₄ H₉, --CH₂ NHCONHCH(CH₃)₂, --CH₂NHCONH(1-napthyl), --CH₂ NHCONH(1-adamantyl), CO₂ H, ##STR94## H, Cl,NO₂, CF₃, CH₂ OH, Br, F, I, methyl, ethyl, n-propyl, isopropyl, n-butyl,sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl,cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl,1-oxopentyl, 1, 1-dimethoxypropyl, 1, 1-dimethoxypentyl, hydroxyalkyl,halo, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,1,1-difluoro-2-phenylethyl, 1, 1-difluoro-2 -cyclohexylethyl,2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl,1,1-difluoropentyl, benzyl, 2-phenylethyl, 1, 1-difluoro-3-phenylpropyl,cyclohexylmethyl, cyclohexanoyi, 1-butenyl, 2-butenyl, 3-butenyl,1-butynyl, 2-butynyl, 3-butynyl and difluoromethyl; wherein each of R³through R¹¹ is hydrido with the proviso that at least one of R⁵, R⁶, R⁸and R⁹ is an acidic group selected from CO₂ H, SH, PO₃ H₂, SO₃ H,CONHNH₂, CONHNHSO₂ CF₃, OH,or a tautomer thereof or apharmaceutically-acceptable salt thereof.
 8. The method of claim 7wherein m is one; wherein R¹ is selected from methyl, ethyl, n-propyl,isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl,n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl,cyclohexylmethyl, 2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and2-hydroxybutyl; wherein R² is selected from ethyl, n-propyl, isopropyl,n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl,neopentyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl, 1,1-difluoro-2phenylethyl,1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl,1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl, 1,1-difluoroethyl,1, 1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl,2-phenylethyl, 1,1-difluoro-3-phenylpropyl, cyclohexylmethyl,cyclohexanoyl, acetyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl,2-butynyl, 3-butynyl, propylthio and butylthio; wherein each of R³through R¹¹ is hydrido with the proviso that at least one of R⁵, R⁶, R⁸and R⁹ is an acidic group selected from CO₂ H, SH, PO₃ H₂, SO₃ H,CONHNH₂, CONHNHSO₂ CF₃, OH,or a tautomer thereof or apharmaceutically-acceptable salt thereof.
 9. The method of claim 8wherein said therapeutically-effective compound is selected fromcompounds of Formula II ##STR95## wherein m is one; wherein R¹ isselected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, phenyl,benzyl, phenethyl, cyclohexyl, cyclohexyimethyl, 2-butenyl, 3-butenyl,2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R² is selected fromethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl,n-pentyl, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl,2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl,1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl,cyclohexylmethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl,1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein R⁵ isan acidic group selected from CO₂ H and ##STR96## or a tautomer thereofor a pharmaceutically-acceptable salt thereof.
 10. The method of claim 9wherein said therapeutically-effective compound is selected fromcompounds, and their pharmaceutically-acceptable salts, of the groupconsistingof5-[2-[6-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;5-[2-[6-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;5-[2-[6-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;5-[2-[6-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;5-[2-[6-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]-3pyridinyl]phenyl]-1H-tetrazole;5-[2-[6-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]-3pyridinyl]phenyl]-1H-tetrazole;5-[2-[6-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]-3pyridinyl]phenyl]-1H-tetrazole;5-[2-[6-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]-3pyridinyl]pheny1]-1H-tetrazole;5-[2-[6-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;5-[2-[6-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]-3pyridinyl]phenyl]-1H-tetrazole;5-[2-[6-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;5-[2-[6-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;5-[2-[6-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole;5-[2-[6-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole; 5-[2-[6-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5yl)methyl]- 3-pyridinyl]phenyl]-1H-tetrazole; and 5-[2-[6-[(1-butyl-3-(2 -phenylethyl)-1H-1,2,4-triazol-5yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole.
 11. Themethod of claim 8 wherein said therapeutically-effective compound isselected from compounds of Formula III ##STR97## wherein m is one;wherein R¹ is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl,sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl,phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 2-butenyl,3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R² isselected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,4-methylbutyl, n-pentyl, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl,2-cyclohexylethyl, 1, 1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,1,1 -difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl,1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl,cyclohexylmethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl,1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein R⁵ isan acidic group selected from CO₂ H and ##STR98## or a tautomer thereofor a pharmaceutically-acceptable salt thereof.
 12. The method of claim11 wherein said therapeutically-effective compound is selected fromcompounds, and their pharmaceutically-acceptable salts, of the groupconsistingof5-[2-[5-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;5-[2-[5-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;5-[2-[5-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;5-[2-[5-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]-2pyridinyl]phenyl]-1H-tetrazole;5-[2-[5-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;5-[2-[5-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;5-[2-[5-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;5-[2-[5-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]-2pyridinyl]phenyl]-1H-tetrazole;5-[2-[5-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;5-[2-[5-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;5-[2-[5-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;5-[2-[5-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole;5-[2-[5-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole; 5-[2-[5-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]-2pyridinyl]phenyl ]-1H-tetrazole; 5-[2-[5-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole; and5-[2-[5-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]-2-pyridinyl]phenyl]-1H-tetrazole.
 13. Themethod of claim 8 wherein said therapeutically-effective compound isselected from compounds of Formula IV ##STR99## wherein m is one;wherein R¹ is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl,sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl,phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 2-butenyl,3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R² isselected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,4-methylbutyl, n-pentyl, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl,2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl,1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl,cyclohexylmethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl,1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein R⁵ isan acidic group selected from CO₂ H and ##STR100## or a tautomer thereofor a pharmaceutically-acceptable salt thereof.
 14. The method of claim13 wherein said therapeutically-effective compound is selected fromcompounds, and their pharmaceutically-acceptable salts, of the groupconsistingof5-[2-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[2-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[2-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[2-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[2-[4-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3pyridinyl]-1H-tetrazole;5-[2-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[2-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[2-[4-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[2-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[2-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[2-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[2-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[2-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[2-[4-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[2-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;and 5-[2-[4-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole.
 15. Themethod of claim 8 wherein said therapeutically-effective compound isselected from compounds of Formula V ##STR101## wherein m is one;wherein R¹ is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl,sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl,phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 2-butenyl,3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R² isselected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,4-methylbutyl, n-pentyl, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,1,1-difluoro-2-phenylethyl, 1,1-difluoro-2-cyclohexylethyl,2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl,1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl,cyclohexylmethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl,1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein R⁵ isan acidic group selected from CO₂ H and ##STR102## or a tautomer thereofor a pharmaceutically-acceptable salt thereof.
 16. The method of claim15 wherein said therapeutically-effective compound is selected fromcompounds, and their pharmaceutically-acceptable salts, of the groupconsistingof5-[3-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]- 4-pyridinyl]- 1H-tetrazole;5-[3-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;5-[3-[4-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;5-[3-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-4-pyridinyl]-1H-tetrazole;and5-[3-[4-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-4-pyridinyl]-1H-tetrazole.17. The method of claim 8 wherein said therapeutically-effectivecompound is selected from compounds of Formula VI ##STR103## wherein mis one; wherein R¹ is selected from methyl, ethyl, n-propyl, isopropyl,n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl,neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl,2-butenyl, 3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; whereinR² is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,isobutyl, 4-methylbutyl, n-pentyl, 1-oxo-2-phenylethyl,1-oxo-2-cyclohexylethyl, 1,1-difluoro-2-phenylethyl,1,1-difluoro-2-cyclohexylethyl, 2-cyclohexylethyl,1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl, 1,1-difluoroethyl,1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, benzyl,2-phenylethyl, 1,1-difluoro-3-phenylpropyl, cyclohexylmethyl,cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-butynyl, 2-butynyl,3-butynyl, propylthio and butylthio; wherein R⁵ is an acidic groupselected from CO₂ H and ##STR104## or a tautomer thereof or apharmaceutically-acceptable salt thereof.
 18. The method of claim 17wherein said therapeutically-effective compound is selected fromcompounds, and their pharmaceutically-acceptable salts, of the groupconsistingof5-[4-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[4-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[4-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[4-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole; 5-[4-[4-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3pyridinyl]-1H-tetrazole;5-[4-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[4-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[4-[4-[(1-butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[4-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[4-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[4-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[4-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[4-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[4-[4-[(1-butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;5-[4-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-3-pyridinyl]-1H-tetrazole;and 5-[4-[4-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-3-pyridinyl]-1H-tetrazole.
 19. Themethod of claim 8 wherein said therapeutically-effective compound isselected from compounds of Formula VII ##STR105## wherein m is one;wherein R¹ is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl,sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl,phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 2-butenyl,3-butenyl, 2-butynyl, 3-butynyl and 2-hydroxybutyl; wherein R² isselected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl,4-methylbutyl, n-pentyl, 1-oxo-2-phenylethyl, 1-oxo-2-cyclohexylethyl,1,1-difluoro-2-phenylethyl, 1,1 -difluoro-2-cyclohexylethyl,2-cyclohexylethyl, 1,1-difluoro-3-cyclohexylpropyl, 1,1-dimethoxybutyl,1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl,1,1-difluoropentyl, benzyl, 2-phenylethyl, 1,1-difluoro-3-phenylpropyl,cyclohexylmethyl, cyclohexanoyl, 1-butenyl, 2-butenyl, 3-butenyl,1-butynyl, 2-butynyl, 3-butynyl, propylthio and butylthio; wherein R⁵ isan acidic group selected from CO₂ H and ##STR106## or a tautomer thereofor a pharmaceutically-acceptable salt thereof.
 20. The method of claim19 wherein said therapeutically-effective compound is selected fromcompounds, and their pharmaceutically-acceptable salts, of the groupconsistingof5-[3-[4-[(1-butyl-3-methyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-ethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-propyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-isopropyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;5-[3-[4-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole; 5-[3-[4-[(1-butyl-3-secbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-isobutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;5-[3-[4-[(1 -butyl-3-tertbutyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-pentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-isopentyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-cyclohexyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-cyclohexylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;5-[3-[4-[[1-butyl-3-(2-cyclohexylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole;5-[3-[4-[(1 -butyl-3-phenyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;5-[3-[4-[(1-butyl-3-phenylmethyl-1H-1,2,4-triazol-5-yl)methyl]phenyl]-2-pyridinyl]-1H-tetrazole;and5-[3-[4-[[1-butyl-3-(2-phenylethyl)-1H-1,2,4-triazol-5-yl]methyl]phenyl]-2-pyridinyl]-1H-tetrazole.21. The method of claim 12 wherein said therapeutically-effectivecompound is5-[2-[5-[(1,3-dibutyl-1H-1,2,4-triazol-5-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole.22. The method of claim 1 wherein said circulatory disorder is acardiovascular disorder.
 23. The method of claim 22 wherein saidcardiovascular disorder is hypertension.
 24. The method of claim 22wherein said cardiovascular disorder is congestive heart failure.